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ABSTRACT 
 
Thyroid dysfunction is one of the most common endocrine disorders in women of childbearing 
age and the obstetric consequences of abnormal thyroid hormone levels during pregnancy have 
been established. Less understood is the implication of the presence of maternal thyroid 
autoantibodies on infant outcomes among women who are euthyroid during pregnancy. The 
objective of this study was two-fold: 1) to examine the influence of antenatal thyroperioxidase 
(TPO) status on fetal/infant brain and body growth measurements at delivery and 2) to explore 
the relationship of antenatal TPO status and maternal postpartum thyroid dysfunction (PPTD)  
on early infant growth and neurocognitive development.  Six-hundred thirty-one (631) euthyroid 
pregnant women were recruited from prenatal clinics in Tampa Bay, Florida and the surrounding 
area between November 2007 and December 2010. TPO status was determined during 
pregnancy and fetal/infant brain and body growth variables were assessed at delivery. A 
subsample of forty-one (41) mother-infant dyads participated in a 6-month longitudinal 
supplemental study.  Infant growth assessments were conducted at 3, 4, 5 and 6 months 
postpartum.  Regression analysis revealed maternal TPO positivity was significantly associated 
with smaller head circumference, reduced brain weight and lower brain-body-ratio; however 
maternal race/ethnicity was identified as an effect modifier in the relationship. No significant 
differences were noted in birth weight, birth length, abdominal circumference or chest 
circumference measurements among infants born to TPO positive mothers of any racial/ethnic 
group as compared to their negative counterparts. Mixed model analysis of the smaller subset 
(n=41) revealed infants of TPO+ mothers were smaller at birth but experienced accelerated 
growth between birth to 3 months when compared to infants born to TPO- mothers. This 
acceleration led to their catch-up in growth to their TPO negative counterparts by 3 months of 
age.  No significant differences were noted in neurocognitive outcomes between infants born to 
vii  
TPO+ mothers compared to those born to TPO- mothers. The findings in this dissertation 
indicate that maternal/race ethnicity modifies the relationship between TPO positivity and 
reduced fetal/infant brain growth. Additionally, the analyses suggest that maternal autoantibody 
status could lead to variations in early infant growth and development. The end-result of these 
variations is unclear.  Further research is needed to determine the potential impact of reduced 
head circumference and accelerated growth as it relates to long-term neurocognitive 
consequences.  Currently, TPO antibody status is not assessed as part of the standard prenatal 
care laboratory work-up, but findings from this study suggest that fetal brain growth may be 
impaired by TPO positivity among certain populations, therefore autoantibody screening among 
high-risk sub-groups may be useful for clinicians to determine whether prenatal thyroid 
treatment is warranted. 
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CHAPTER ONE 
 
Introduction and theoretical framework 
 
Thyroid dysfunction is one of the most common endocrine disorders in women of 
childbearing age 
Specific Aims 
 
(1), second only to diabetes mellitus. Approximately 2-3% of women are 
diagnosed prenatally with abnormal thyroid function however; a greater number may go 
undetected due to lack of consensus on testing and treatment during pregnancy (2-4). Normal 
maternal thyroid function is critical for early fetal development, as the fetus does not produce 
thyroid hormones until the end of the first trimester (~12-14 weeks gestation) and prior to that 
time is solely dependent on the mother’s hormone supply (5-7). The impact of thyroid 
dysfunction, particularly hypothyroidism, during pregnancy has been well documented (8, 9) and 
the associated adverse fetal/infant outcomes range from preterm delivery to fetal death (10-14). 
Abnormal maternal thyroid hormone levels during gestation have also been associated with 
long-term effects in older offspring including delayed learning, lowered IQ and hearing deficits 
(14-17). 
Thyroid autoantibodies, an indicator of autoimmunity, are found in 10% of 
pregnant women, but are not necessarily accompanied by thyroid dysfunction (15). Despite the 
greater likelihood of the presence of thyroid autoantibodies, their influence during pregnancy is 
less-understood, particularly among women who are biochemically euthyroid, or exhibit thyroid 
hormone levels within normal limits.  Limited research has suggested that thyroperioxidase 
(TPO) antibody positivity, independent of abnormal thyroid levels, may increase the risk of 
placental abruption, spontaneous miscarriage and perinatal death (11, 13, 18-23). Even fewer 
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studies have assessed the impact of maternal TPO antibody status on infant specific variables 
such as anthropometric measurements at delivery and such studies have produced conflicting 
results (21, 24). Additionally, the long-term impact of maternal TPO status on the offspring has 
also been understudied. To further explore the relationship between maternal autoantibody 
status and fetal/infant growth outcomes we undertake this study with the overarching hypothesis 
that infants born to TPO+ mothers will exhibit impaired growth and neurocognitive outcomes. 
This hypothesis is tested in a cross-sectional study of 631 women recruited in a National 
Institutes of Health R01 study (Principal Investigator: Maureen Groer, RN, PhD, FAAN) on 
trajectories of postpartum thyroiditis.  Additionally, 41 mother-infant dyads were included in a 
longitudinal sub-analysis of infant neuro-cognitive outcomes at 6 months of age. This study was 
funded by a National Institute of Health Diversity Supplement and the specific aims include: 
1. To investigate the association between maternal thyroperoxidase 
antibody status during pregnancy and fetal/infant body growth variables. 
2) To determine the influence of maternal thyroperoxidase antibody status 
fetal/infant brain growth variables 
3)To explore the relationship of thyroperoxidase status and early infant growth 
and neuro-cognitive development. 
. 
The thyroid gland, a “butterfly” shaped bi-lobed structure, is one of the largest of the 
endocrine organs weighing approximately 15-20 grams in adults(
Thyroid Gland 
 
25). It is positioned anterior to 
the trachea just above the sternal notch. The right and left lobes, which are about 4 centimeters 
in length (from top to bottom), wrap around the trachea to attach to the upper front of the  
trachea and the lower region of the larynx(25). The potential for thyroid gland growth is 
considerable, with an enlarged gland termed a “goiter”. 
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Most of the thyroid tissue consists of follicular cells. The thyroid follicle is the 
functional unit for thyroid hormone synthesis and storage. Thyroid cells produce 2 main 
hormones: Thyroxine (T4) and Triiodothyronine (T3). The thyroid gland is specialized to 
synthesize and secrete T4 and T3 into the circulation. This process is regulated by thyroid- 
stimulating hormone (TSH or thyrotropin) secreted from the pituitary gland. The pituitary gland 
is stimulated by thyrotropin-releasing hormone (TRH) from the hypothalamus. Both TSH and 
TRH are regulated in a negative-feedback loop by circulating T4 and T3(26). Figure 1.1 
provides a schematic overview of thyroid hormone production. 
Several components are required for the synthesis of thyroid hormones. The 
necessary components include iodine, thyroid peroxidase (TPO), thyroglobulin, and hydrogen 
peroxide (H2O2). The thyroid contains 70–80% of the total iodine in the body, roughly15–20 
mg(25). The gland must capture approximately 60 μg of iodine or iodide from the circulation to 
maintain adequate thyroid hormone production (25, 27). Inorganic iodine is transported into the 
thyroid by the sodium/iodide symporter (NIS), where it is oxidized by the TPO-H2O2 system, 
and then utilized to iodinate tyrosyl residues in thyroglobulin. T4 and T3 are then produced by 
the coupling of iodinated tyrosyl intermediates in the TPO-H2O2 system (25, 27). The 
hormones are hydrolyzed and secreted into the circulation(25). The processes are so 
interconnected that malfunction in any of the components can lead to impairment of thyroid 
hormone production or secretion. 
 
The overall effect of pregnancy is an increased demand on the thyroid gland(
Thyroid Function During Pregnancy 
 
28). 
Pregnancy induces normal physiologic changes that may affect thyroid volume and function. A 
daily iodine intake of 250 µg is recommended during pregnancy (compared to daily 
recommended amount of 150 µg for non-pregnant women) to accommodate the significant 
changes in iodine metabolism that occur during gestation (26, 29).This increase in daily iodine 
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intake is not always achieved, thus to prevent fetal brain damage (due to iodine insufficiency) 
additional iodine supplementation may be required in areas of suboptimal iodine nutrition (29). 
During pregnancy, synthesis of thyroid hormones is thought to increase by up to 
50% due to estrogen-induced increase in thyroxine-binding globulin (TBG) concentration (28, 
30, 31). However, depending on the assays used and the hormone measured, serum 
concentration of thyroid hormones has been reported to be decreased, increased or unchanged 
during pregnancy(26). Assays measuring total T4 show an increase approximately 1.5 times the 
non-pregnant value. There is general consensus that there is a transient rise in free T4 (fT4) in 
the first trimester due to the relatively high circulating human chorionic gonadotrophin (hCG) 
concentration and a decrease of free T4 in the second and third trimester, however it remains 
within the normal reference range (28). Changes in free triiodothyronine (fT3) concentration are 
also seen in which it parallels the concentration of fT4, again within the normal range. 
The placenta secretes human chorionic gonadotropin (hCG) in the first week 
after conception and the level is the highest at week 10 before it begins to decrease (26, 29) 
and reach a plateau at week 20 (26, 29). hCG acts as a thyroid-stimulating hormone (TSH) 
agonist so that elevated levels contribute to the occurrence of gestational transient 
hyperthyroidism, which occurs in 2–3% of pregnancies (29). The hCG and TSH molecules 
share similarities, as do the hCG and TSH receptors. Consequently, hCG weakly stimulates the 
thyroid gland and TSH receptor stimulation depends on the amplitude and duration of the hCG 
peak. 
Serum TSH concentrations usually provide the first clinical indicator of thyroid 
dysfunction in a non-pregnant female. Due to the loglinear relationship between TSH and fT4, 
very small changes in T4 concentrations will result in very large changes in serum TSH (29). 
However, in early gestation, TSH is suppressed by 20–50% by week 10 due to the steep 
increase in hCG concentrations and its measurement at this time may not provide a good 
indicator for either the diagnosis or the control of treatment of thyroid dysfunction(29). 
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Therefore, it is essential to rely on T4 and T3 (either bound or free) to assess thyroid status in 
early gestation, although TSH will be significantly elevated in overt hypothyroidism. Later in 
gestation (from about 16 weeks on) TSH is more reflective of thyroid status(26). 
 
 
Prior to 12-14 weeks gestation the fetus does not produce its own thyroid 
hormone and must rely solely on hormone production and supply from the mother. Adequate 
maternal T4 andT3 are critical for development of the fetal brain(
Maternal Thyroid Function and Fetal Brain Development 
 
32). The fetus does not 
produce its own thyroid hormone in appreciable amounts until the third trimester(32). 
Additionally, it is not until term that full thyroid function is achieved. 
 
Impact of Thyroid Autoantibodies 
 
Although the measurement of thyroid antibodies (i.e., thyroid 
peroxidaseantibodies) does not give any indication of thyroid status, their presence does have 
significant implications during pregnancy. TPO antibodies are a marker for an increased risk of 
infertility, miscarriage and preterm delivery(33). TPO antibodies are found in around 10% of 
women in early pregnancy and are also associated with decreased thyroid functional reserve 
during gestation (15, 26).  Additionally, the presence of TPO antibodies in early pregnancy 
imparts a 50% risk for the development of postpartum thyroid dysfunction (34-37). 
Many thyroid disorders are autoimmune in nature and are characterized by the 
presence of autoantibodies. These autoantibodies substantially contribute to the pathogenesis 
of several thyroid disorders as they attack the thyroid gland and disrupt its function (38), 
potentially causing long term problems for the mother and infant. Pop et al(17) reported a  
strong relation between the presence of antithyroid peroxidase during pregnancy and impaired 
development in the offspring. A study by Kvetny&Hedvig(39) describes a congenital transient 
hyperthyroidism in neonates of mothers with raised levels of thyroid peroxidase autoantibodies 
during pregnancy. They hypothesize that these autoantibodies produce a cytotoxic effect on the 
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neonate thyroid and because brain growth and development extends beyond the neonatal 
period, this transient hyperthyroidism has the potential to impair subsequent neurodevelopment 
of the infant. In the same fashion that maternal thyroid peroxidase (TPO) antibodies cross the 
placenta and attack the fetal thyroid gland, a similar situation may occur through the transfer of 
maternal autoantibodies in breast milk. A study by Tornhage&Grankvist(40) reported that TSH- 
receptor antibody (TRAb) positive mothers may cause transient neonatal thyroid disease in the 
infant and this condition may be worsened and more prolonged as a consequence of TRAb in 
breast milk. These previously published reports have provided evidence that neonatal thyroid 
disease caused by transmission of maternal autoantibodies in utero and in breast milk could 
lead to complications in infant growth and development postpartum (39, 40). 
 
 
Hypothyroid or hyperthyroid thyroid dysfunction (PPTD) occurs in 4%-10% of women within the 
first 6 months following parturition (
Postpartum Thyroid Dysfunction 
 
17, 41-45). Incidence of postpartum thyroid disorders seems 
to be higher among pregnant women with a goiter, Hashimoto's thyroiditis, a strong family 
history of autoimmune thyroid disorders, or type 1 (insulin-dependent) diabetes mellitus(45). 
Dysfunction is usually transient but may require treatment. 
 
Silent lymphocytic thyroiditis (postpartum thyroiditis) is a recently recognized 
postpartum disorder which develops abruptly in the first few weeks following delivery and is 
responsible for most cases of postpartum thyroid dysfunction  (45). Its clinical course is 
characterized by mild hyperthyroid symptoms occurring 4-8 weeks postpartum or later. The 
thyroid-stimulating hormone (TSH) level is suppressed, and thyroxine (T4), triiodothyronine (T3), 
and antibody titers are elevated. The thyroid gland may become enlarged but is painless. 
Lymphocytic infiltration is present and radioactive iodine uptake is typically low (a high uptake 
would be more consistent with Graves' disease). The hyperthyroid phase may last 1 to 2 months 
(46) and is typically followed by a hypothyroid phase between 12 and 24 weeks postpartum 
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(47). The hypothyroid phase is characterized by clinical symptoms, low T4 level, elevated TSH 
level, and further elevation of antibody titers. Thyroid peroxidase autoantibodies (TPO) and, less 
commonly, antithyroglobulin antibodies are almost always positive during pregnancy and the 
postpartum period. The clinical course may vary, with some mothers experiencing only the 
hyperthyroid phase and others only the hypothyroid phase; however, spontaneous resolution 
occurs in most women after several weeks or months. Treatment in the early postpartum period 
is typically limited to symptomatic women only. 
In iodine sufficient areas, the exact cause of PPTD is unknown but it is 
hypothesized to be the result of an autoimmune process instigated by the suppression of 
cellular immunity during pregnancy and its return postpartum. The propensity for postpartum 
thyroid dysfunctions seems to be related to increasing serum levels of thyroid autoantibodies. 
Women with high antibody titers in early pregnancy commonly are affected postpartum (48). 
Mothers who experience postpartum thyroiditis (hyper-or hypothyroid phase) have about a 30% 
increased risk of developing permanent hypothyroidism (47, 49). Others may develop 
subclinical disease. Half of these women with thyroiditis who are positive for thyroid peroxidase 
antibodies develop permanent hypothyroidism within 6 to 7 years (50). Thus PPTD may have 
long-term implications. 
 
 
Birth weight is one of the most frequently used indicators of fetal growth and 
health throughout pregnancy.  Birth weight, particularly low birth weight (<2500g), has been 
linked to numerous adverse consequences for the neonate, infant and child (
Fetal Brain and Body Growth 
 
51) and can be 
attributed to preterm delivery (<37 weeks gestation) or impaired growth in utero(52). Other 
anthropometric measurements at delivery, such as head and abdominal circumference, are also 
indicative of fetal growth in utero(53). Head circumference is known to correlate closely with 
brain volume(54) and can therefore be used as a proxy for brain growth (55-58). There is 
8  
evidence, although inconsistent, that impaired brain growth in utero and in infancy may lead to 
poorer cognitive function in childhood (58). In a study of 118 low birth weight infants, those 
whose head circumference was in the 10th percentile at birth had a mean IQ at 5 years of age 
that was 17 points lower than that of those whose head circumference was in the 50th percentile 
(59).  In a study of 633 term-born children, head circumference at birth was identified as a 
significant predictor of full-scale, verbal, and performance IQ scores at 4 years of age, however 
postnatal head growth stood out as a predictor of IQ at 8 years of age (58). However, a study 
that examined the relationship between head circumference at birth, as a continuous variable, 
and IQ among 221 children at 9 years of age found no statistically significant association (57). 
 
 
The impact of early life influences on future neurodevelopmental outcomes has 
received increasing attention. The first 2 years of life represent a critical period for 
neurodevelopment (
Infant Growth and Neurodevelopment 
 
60, 61). During this time the brain develops through the processes of 
neurogenesis, cell growth and death, myelination and gliogenesis(62).  Disruption in any of 
these processes may have far-reaching and long-term effects (60, 63). Poor infant growth, 
indicated by low infant weight or reduced weight gain, is one factor that has been linked to 
neuro-developmental impairments and lowered cognition later in life (64). Similar to Barker’s 
Hypothesis of fetal programming and adult disease (65, 66), recent research has also shown 
that experiences during infancy may predispose some to disease or disorders in adulthood (67, 
68). Thus infancy remains a critical period in this developmental pyramid and insults occurring 
during this time could have far-reaching consequences that could influence quality of life 
subsequently. 
Several studies have assessed the effect of abnormal thyroid function during 
pregnancy on the fetus/infant but few have examined the impact of postpartum thyroid 
dysfunction (PPTD) on the offspring (17). Pop et al investigated the impact of maternal thyroid 
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dysfunction and depression during pregnancy and postpartum on child development during the 
preschool years (17).  Using the McCarthy Scales of Children’s Abilities (MSCA) to assess child 
development at 5 years of age, they did not find a significant difference in scores among 
preschoolers of mothers who experienced PPTD compared to mothers who did not experience 
PPTD. They did, however, report that children of mothers who were anti-thyroid peroxidase 
antibody positive postpartum or who experienced postpartum depression tended to score lower 
on the MSCA.  Among the study limitations noted by the investigators was the assessment of 
child development several years following delivery and the potential influence of environmental 
factors that could not be taken into account. 
 
 
Findings from this research could contribute meaningful information to the debate on prenatal 
TPO autoantibody testing. Currently, the Endocrine Society Clinical Practice Guidelines 
recommend targeted case finding during early pregnancy or only screening pregnant women 
who are at high-risk of thyroid disease (women with personal or family history of thyroid disease 
or a history of other autoimmune disease). However, such practice may miss 30–50% of women 
with autoimmune thyroid disease that would benefit from treatment (
Public Health Implications 
 
69, 70) and findings from 
recent studies (71) indicate that substitutive treatment with Levothyroxine may lower the chance 
of adverse obstetric outcomes (miscarriage and premature delivery) among euthyroid pregnant 
women who are positive for TPO autoantibodies. Additionally, several cost-effectiveness 
analyses have shown that universal screening of pregnant women for autoimmune thyroid 
disease is cost-effective compared with no screening and/or high-risk screening only (72-74). 
Therefore, universal screening of pregnant women for TPO autoantibodies has the potential to 
be cost-effective intervention method of improving fetal/infant outcomes among the offspring of 
affected mothers. 
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Considering the long-term implications of impaired fetal/newborn growth it is 
important to identify any avenues of early prevention and intervention. Maternal thyroid 
antibody status during pregnancy may be one of those factors that plays a role in fetal growth 
impairment but is currently being overlooked due to lack of consensus on maternal testing and 
treatment.  Additionally, examining the relationship between maternal postpartum thyroid 
dysfunction and infant developments is important because 4%-10% of women suffer from 
thyroid dysfunction following childbirth (
Summary 
 
41-44, 75) and the postpartum period remains a critical 
time for mother and infant. This study provides an opportunity to contribute to the limited 
information published on maternal thyroid antibody status and newborn brain and body growth, 
and the potential impact of maternal thyroid dysfunction during the postpartum period. 
 
 
 
 
Figure 1.1 Schematic of thyroid hormone synthesis (26) 
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CHAPTER TWO 
 
 
Manuscript 1: Impact of maternal thyroperoxidase status on fetal body and brain size 
 
 
 
Currently, TPO antibody status is not assessed as part of the standard prenatal care laboratory 
work-up, but findings from this study suggest that fetal brain growth may be impaired by TPO 
positivity among certain populations, therefore autoantibody screening among high-risk sub- 
groups may be useful for clinicians to determine whether prenatal thyroid treatment is 
warranted. 
Abstract 
 
The obstetric consequences of abnormal thyroid function during pregnancy have been 
established. Less understood is the influence of maternal thyroid autoantibodies on infant 
outcomes. The objective of this study was to examine the influence of maternal 
thyroperioxidase (TPO) status on fetal/infant brain and body growth. Six-hundred thirty-one 
(631) euthyroid pregnant women were recruited from prenatal clinics in Tampa Bay, Florida and 
the surrounding area between November 2007 and December 2010. TPO status was 
determined during pregnancy and fetal/infant brain and body growth variables were assessed at 
delivery. Regression analysis revealed maternal TPO positivity was significantly associated with 
smaller head circumference, reduced brain weight and lower brain-body-ratio; however maternal 
race/ethnicity was identified as an effect modifier in the relationship.  No significant differences 
were noted in body growth measurements among infants born to TPO positive mothers. 
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Thyroid dysfunction is one of the most common endocrine disorders in women of childbearing 
age 
Introduction 
 
(1), second only to diabetes mellitus. Approximately 2-3% of women are diagnosed 
prenatally with abnormal thyroid function; however; a greater number may go undetected due to 
lack of consensus on testing and treatment modalities during pregnancy (2-4). Normal maternal 
thyroid function is critical for early fetal development, as the fetus does not produce thyroid 
hormones until the end of the first trimester (~12-14 weeks gestation) and, prior to that time, is 
solely dependent on the mother’s hormone supply (5-7). The impact of thyroid dysfunction, 
particularly hypothyroidism, during pregnancy is well documented (8, 9), and the associated 
adverse fetal/infant outcomes range from preterm delivery to fetal death (10-14). Abnormal 
maternal thyroid hormone levels during gestation are also linked to long-term effects in older 
offspring including delayed learning, lowered IQ and hearing deficits (14-17). 
 
 
A number of women may be biochemically euthyroid, or exhibit thyroid hormone levels within 
normal limits, but test positive for thyroid autoantibodies such as thyroperioxidase (TPO) 
antibody.   In fact, it is estimated that 10% of pregnant women are TPO positive (15); however, 
fewer studies have assessed the influence of TPO status on fetal/ infant outcomes among 
euthyroid mothers.  Limited research tends to suggest that TPO positivity, independent of 
abnormal thyroid levels, may increase the risk of placental abruption, spontaneous miscarriage 
and perinatal death (11, 13, 18-23, 76). Even fewer studies have assessed the impact of 
maternal TPO antibody status on infant specific variables such anthropometric measurements 
at delivery although these studies have produced conflicting results (21, 24). To further explore 
the relationship between maternal autoantibody status and infant outcomes, this study uniquely 
examined the influence of maternal TPO status on fetal/infant brain growth at delivery, which 
has been linked to cognitive function in childhood (58, 59). This project was undertaken with the 
following hypotheses: 1) at delivery, newborns of TPO+ mothers will exhibit impaired body 
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growth as indicated by reduced birth weight and birth length; and 2) at delivery, infants born to 
TPO+ mothers will exhibit impaired brain growth as exhibited by reduced head circumference 
and calculated brain weight. 
 
 
Thyroperoxidase antibody (TPO) status was the exposure of interest. TPO status was 
determined in 631 plasma samples according to kit directions by ELISA (ORGENTEC, Mainz, 
Germany) using standards and controls. All samples were collected in duplicate and titers 
recorded. The coefficient of variation was always less than 5%. TPO antibody titer greater than 
Methods 
 
Participants 
 
Pregnant women (N = 631) were recruited from prenatal clinics in Tampa, Florida and the 
surrounding area between November 2007 and December 2010. Women were eligible for 
participation in the study if they were between 18 and 45 years of age, 16 to 25 weeks’ 
gestation, could understand and speak the recruiter’s language (English or Spanish), and were 
essentially healthy without plans to terminate the pregnancy or relocate prior to 6 months post- 
partum.  Exclusion criteria included: known autoimmune disease, previous thyroid disease, 
presence of chronic diseases/conditions including HIV, use of medications that affect immunity, 
mental illness, body mass index (BMI) <20, current multiple gestation, current pregnancy 
product of in-vitro fertilization (IVF), and fetal abnormalities. All women were biochemically 
euthyroid.  Thyroperoxidase antibody status was measured for all participants at the time of 
enrollment and women were classified as TPO positive or negative. Thyroid stimulating  
hormone (TSH) levels were measured for all TPO-positive women at the time of enrollment. The 
study was approved by the University of South Florida Institutional Review Board. All 
participants gave full written informed consent. 
 
 
Exposure Assessment 
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20 IUs/ml was used as the cutoff value for determining positivity, since a value from 0 to 20 is 
considered within normal range (13). TPO status was categorized as positive or negative. 
 
 
Outcome Assessment 
 
Newborn anthropometric measurements were retrieved from maternal delivery records including 
ultrasound-derived gestational age in weeks, birth weight (grams), birth length (centimeters 
(cm)), head circumference (cm), abdominal circumference (cm) and chest circumference (cm). 
Infant head circumference at birth was used to derive two additional indices of fetal brain size: 
brain weight and brain-to-body ratio (BBR). Brain weight was estimated from the following 
formula: brain weight (g) = 0.037 × head circumference (cm)2.57, which is derived from the 
National Institute of Neurological and Communicative Disorders and Stroke’s Collaborative 
Perinatal Project (77). Brain-to-body ratio (BBR)was defined as 100 × the ratio of the infant’s 
estimated brain weight to its birth weight. This is the percentage of the infant’s birth weight that 
is estimated to reside in the brain. Since the brain weight is a function of the head 
circumference, the formula could be re-written in terms of birth weight and head circumference 
thus: BBR = 100 × [0.037 × head circumference (cm)2.57]/birth weight(g). A high BBR is 
indicative of a higher proportion of birth weight residing in the brain, while a lower BBR indicates 
a lower percentage of birth weight residing in the brain (78). Typical values for healthy infants 
are 9-10% (78). 
 
 
Study Sample 
 
Delivery records for 52 participants were not available at the time of analysis.  For the current 
study, multiple gestation pregnancies (n=6) and pregnancies resulting in fetal demise (n=4) 
were excluded.  To promote homogeneity of the sample and reduce confounding factors, 
analysis was restricted to term infants only (>=37 weeks gestation), resulting in a final study 
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sample of 528 women who delivered term infants. Figure 2.1 provides an overview of the study 
sample. 
 
 
Statistical Analysis 
 
Maternal thyroid status was a categorical determinant in this analysis. Chi-square test and two 
sample t-test were used to assess differences in socio-demographic characteristics between 
TPO+ and TPO- mothers. Mean differences in growth parameters were examined by maternal 
TPO status using t-test. Multivariate statistical techniques were used to demonstrate the 
influence of TPO status on the continuous outcomes: birth weight, birth length, head 
circumference, abdominal circumference and chest circumference. With multiple outcomes, 
there is concern of inflated error rates if each outcome is tested separately(79). Additionally, the 
birth outcomes of interest were correlated with each other; thus, conducting separate test of 
each outcome would result in reanalyzing some of the same variance. Multivariate analysis 
allows measurement of multiple outcomes/dependent variables without violation of acceptable 
levels of Type I error (79). Specifically, seemingly unrelated regression (SUR), a multivariate 
technique, was used to estimate models simultaneously while accounting for the correlated 
errors, leading to efficient estimates of the coefficients and standard errors(80). SUR also 
permitted each model to be estimated simultaneously even when the independent 
variables/predictors varied. 
 
 
The covariates in the regression models were selected à priori based on information in the 
published literature. These variables included maternal age, parity, race/ethnicity (White Non- 
Hispanic; Black Non-Hispanic; Hispanic; Other), marital status, prenatal smoking habits, pre- 
pregnancy body mass index (BMI), delivery type and gender of the infant. Several variables 
were dichotomized in the regression models: parity (nulliparous*, multiparous), marital status 
(married*, unmarried), smoking habits (smoker, nonsmoker*), pre-pregnancy BMI (overweight 
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[BMI>25], non-overweight*), delivery type (vaginal*, cesarean) and infant gender (male*, 
female). The * denotes the referent category for each variable. Additionally, adjusted estimates 
were derived in all cases by using TPO negative participants as the referent category. 
 
 
A combination of graphic methods and statistical tests were used to check for violations of the 
regression assumptions. After fitting the linear regression models to the data, the normality 
assumption was assessed by visual inspection of the residual normal QQ plots and by use of  
the Shapiro-Wilk test.  Visual inspection of residual scatter plots of outcome variables and errors 
of prediction were evaluated to ensure the homoscedasity assumption was not violated. 
Variance inflation and tolerance values were used to assess multicollinearity.  Data for all 
outcome variables in the study sample were 99% complete.  SAS version 9.3 (SAS Institute, 
Cary, NC) was used to perform all analyses. 
 
 
The final study sample (n=528) comprised pregnant women with a mean age of 28.03 ± 5.85 
years (range 18-45).  Nearly 48% (n=253) of the sample were white, 59% (n=309) were married 
and less than 6% (n=30) were smokers. The mean gestational age at delivery of the term 
infants retained in the sample was 39.02 ± 1.10 (range 37-41 weeks).  Approximately 11% 
(n=58) of the final sample tested positive for the thyroperoxidase antibody during pregnancy 
with a mean TPO titer value of 80 ± 60.9 (range 21-244). Table 2.1 depicts selected socio- 
demographic characteristics by maternal TPO status. Women who tested positive for the TPO 
antibody did not differ significantly from their negative counterparts in terms of racial/ethnic 
background, marital status, smoking habits or body mass index. TPO+ mothers tended to be 
older in age and were more likely to deliver female infants, however, neither of these factors 
achieved statistical significance. Analyses of mean gestational age at delivery showed that 
white non-Hispanic and Hispanic mothers were more likely to deliver infants at 39+ weeks 
Results 
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gestation compared to black mothers and mothers in the “Other” racial/ethnic category (see 
Appendix A: Table A.1). No differences were noted in delivery type (vaginal vs. cesarean) or 1 
minute Apgar score. Also, no differences in mean newborn birth weight, birth length, abdominal 
circumference or chest circumference were observed between the two groups (Table 2.2). 
Nonetheless, small but significant differences were noted for the mean head circumference 
measurements among infants born to TPO+ mothers vs. TPO- mothers (34.45 cm ±1.34 SD 
versus 34.86 cm ± 1.45, respectively (p=0.04)).  Additionally, infants born to TPO+ had 
significantly smaller brain weight than those of TPO- mothers. 
 
 
Unadjusted multivariate regression analysis for fetal/infant growth variables at delivery did not 
indicate a significant association between fetal/infant growth and maternal TPO status (Table 
2.3). However, adjusted analysis suggests thatafter controlling for several maternal and 
pregnancy factors a significant relationship exists between maternal TPO status and fetal/infant 
brain growth variables (head circumference, brain weight and brain-to-body ratio) (Table 
2.4).Interestingly, maternal race/ethnicity was identified as an effect modifier in the relationship 
between TPO status and fetal/infant brain growth. In this study population, birth weight, birth 
length, abdominal circumference and chest circumference were not associated with TPO status 
(Table 2.4). Table 2.5 depicts the adjusted means of infant growth variables by maternal TPO 
status. 
 
 
The findings indicate that maternal race/ethnicity modifies the relationship between TPO 
positivity and reduced brain growth measurements at delivery (head circumference, brain weight 
and brain-body-ratio). This analysis was restricted to term births to promote a more 
Discussion 
 
This study examined the relationship between maternal thyroid perioxidase antibody status and 
newborn brain and body growth measurements within a cohort of euthyroid pregnant women. 
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homogenous study sample.  However, additional analysis was conducted to determine whether 
the same relationships persist even when preterm deliveries are included in the analysis. Table 
A.3 in Appendix A presents the adjusted means of infant brain and body growth variables 
including preterm deliveries. Inclusion of preterm deliveries resulted in similar findings and the 
effect modification of maternal race/ethnicity on the relationship between maternal TPO status 
and fetal/infant brain growth variables persisted. 
 
 
The present analysis did not indicate a significant relationship between TPO status and infant 
birth weight in this study sample. This finding is contradictory to those studies who have 
reported increased likelihood of low birth weight infants born to TPO+ mothers (21) and an 
increased likelihood of large-for-gestational age infants born to TPO+ women (21).  Similar to 
previously published studies (21), this analysis did not find a difference in the birth length, 
abdominal circumference or chest circumference of infants born to TPO+ mothers compared to 
those born to TPO- mothers. 
 
 
Although measurement of thyroid antibodies does not give any indication of thyroid function, the 
presence of TPO antibodies may be associated with decreased thyroid functional reserve during 
pregnancy (26, 81). Reduced functional thyroid reserve in combination with the normal 
physiological changes in pregnancy could contribute to minor alterations in circulating thyroid 
hormone concentrations while remaining within the normal reference range (82). Some 
researchers hypothesize that the presence of TPO antibodies during a time of increasing thyroid 
hormone demand such as pregnancy implies that the mother may become hypothyroid during 
gestation and that transient maternal hypothyroidism may ultimately be responsible for the 
adverse outcomes (81, 83, 84). However, previous studies have reported the detrimental  
effects of TPO antibodies independent of abnormal thyroid hormone levels or disorders (13, 21). 
Results of this study support this assumption, as our findings indicate that TPO antibodies are 
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associated with reduced brain growth measurements among infants born to a vulnerable 
subgroup of euthyroid women. 
 
 
A notable strength of this study is the prospective design, as many of the previous studies were 
retrospective in nature (10, 83, 85). Additionally, laboratory analysis of thyroid stimulating 
hormone (TSH) was used to confirm euthyroid state among participating mothers. The outcome 
variables were extracted from maternal delivery records, therefore, measurements were not 
influenced by knowledge of maternal TPO status. One limitation of this study is the lack of data 
on maternal iodine intake, as well as detailed information on smoking habits during pregnancy 
including the amount of cigarettes smoked and changes in smoking habits over the course of 
gestation. Low iodine intake and cigarette smoking may influence maternal thyroid function and 
thus perhaps fetal brain and body development. Even mild iodine deficiency during pregnancy 
may cause meaningful decreases in maternal thyroid hormone levels (86, 87). Although the 
general U.S. population is considered iodine sufficient, data from the National Health and 
Nutrition Survey (NHANES) revealed that the median urinary iodine concentration among 
pregnant women in 2009-2010 was significantly lower than in 2007-2008 (88). Additionally,  
data from NHANES 2005-2010 suggest less than adequate iodine levels are more likely in the 
first or second trimester, when the fetus mostly depends on the mother’s thyroid hormone 
supply.  Furthermore, smoking complicates the issue as thiocyanates from cigarette smoke 
decrease the uptake of iodine into the thyroid gland by competitively inhibiting the sodium/iodide 
transporter (87). 
 
 
After controlling for several maternal and pregnancy factors, TPO positivity was associated with 
smaller head circumference, reduced brain weight and lower brain-body-ratio. However, the 
influence of TPO status on brain growth was modified by maternal race. Future studies should 
focus on the identification of genetic variants or single nucleotide polymorphisms (SNPs), which 
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could elucidate the interaction between maternal TPO status and race/ethnicity.  Epigenetic 
analysis may prompt ethnic-based screening for TPO autoantibodies. This is potentially 
important because findings from recent studies (71) indicate that substitutive treatment with 
Levothyroxine may lower the chance of adverse obstetric outcomes (miscarriage and premature 
delivery) among euthyroid pregnant women who are positive for TPO autoantibodies. 
 
 
Considering the long-term implications of impaired fetal/newborn growth, it is important to 
identify avenues for early prevention and intervention.  Maternal thyroid antibody status during 
pregnancy may be one of those factors that play a role in fetal growth impairment but is 
currently being overlooked due to lack of consensus on maternal testing and treatment.  At 
present, TPO antibody status is not assessed as part of the standard prenatal care laboratory 
work-up, but this study suggests that fetal brain growth may be impaired by TPO positivity 
among certain populations, therefore, autoantibody screening among high-risk sub-groups may 
be useful for clinicians to determine whether prenatal thyroid treatment is warranted. 
 
This study was supported by a research diversity supplement to a National Institutes of Health 
(NIH) grant (R01-NR05000: Principal Investigator: Maureen Groer, RN, PhD, FAAN). Its 
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of NIH. 
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Figure 2.1 Diagram of study population 
22  
Table 2.1 Selected socio-demographic characteristics by maternal TPO status (n=528) 
 
 TPO positive 
(N=58) 
TPO negative 
(N=470) 
 
P-value 
Maternal Age 
Mean (±SD) 
 
29.31 (±6.28) 
 
28.18 (±5.79) 
 
0.19 
Race/Ethnicity  
29 (50.00%) 
 
224 (47.66%) 
 
0.48 White 
Black 8 (13.79%) 97 (20.64%) 
Hispanic 18 (31.03%) 115 (24.46%) 
Other 3 (5.17%) 34 (7.23%) 
Married 
Yes 
 
37 (63.79%) 
 
272 (58.00%) 
 
0.40 
Parity 
Nulliparous 
 
17 (29.82%) 
 
148 (31.56%) 
 
0.79 
Smoking 
Yes 
 
2 (3.45%) 
 
28 (6.00%) 
 
0.76 
Body Mass Index 
Overweight/Obese 
 
39 (67.24%) 
 
301 (64.04%) 
 
0.63 
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Table 2.2 Selected infant characteristics at delivery by maternal TPO status (n=528) 
 
 TPO positive 
N=58 
TPO negative 
N=470 
 
P-value 
Gestational Age at Delivery 
Mean (± SD) 
 
38.98±1.02 
 
39.04±1.11 
 
0.71 
Delivery Type 
Vaginal 
 
38 (65.52%) 
 
321 (68.30%) 
 
0.67 
Gender 
Male 
 
24 (41.38%) 
 
241 (51.28%) 
 
0.15 
1 Minute Apgar 
Apgar < 7 
 
3 (5.17%) 
 
37 (7.87%) 
 
0.60 
Birth Weight (gm) 
mean (± SD) 
 
3374.2 (±418.8) 
 
3407.2 (±461.2) 
 
0.60 
Birth Length (cm) 
mean (± SD) 
 
51.11 (±1.96) 
 
51.02 (±2.17) 
 
0.75 
Head Circumference (cm) 
mean (± SD) 
 
34.45 (±1.34) 
 
34.86 (±1.45) 
 
0.04 
Brain Weight 
mean (± SD) 
 
331.1 (±33.03) 
 
341.5 (±36.27) 
 
0.04 
Brain-to-Body Ratio 
mean (± SD) 
 
9.91 (±1.21) 
 
10.12 (±1.14) 
 
0.19 
Abdominal Circumference (cm) 
mean (± SD) 
 
30.98 (±2.03) 
 
31.35 (±2.09 
 
0.21 
Chest Circumference (cm) 
mean (± SD) 
 
33.24 (1.92) 
 
33.15 (1.95) 
 
0.74 
 
High Birth Weight (HBW) 
 
1 (1.72%) 
 
23 (4.89) 
 
0.50 
 
Low Birth Weight (LBW) 
 
0 (0.00%) 
 
8 (1.70%) 
 
0.61 
 
Small-for-gestational-age (SGA) 
 
4 (6.90%) 
 
31 (6.60) 
 
1.00 
 
Large-for-gestational-age (LGA) 
 
7 (12.07%) 
 
51 (10.85%) 
 
0.78 
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Table 2.3 Unadjusted estimates for the association between maternal TPO status and 
fetal/infant brain and body growth variables 
 
Parameter Estimate SE p-value 
Head -0.37 0.20 0.0639 
Brain Weight -9.41 5.01 0.0609 
Brain-to-Body Ratio -0.20 0.16 0.2232 
Birth Weight -0.03 0.06 0.6593 
Abdominal Circumference -0.37 0.29 0.2094 
Chest Circumference 0.09 0.26 0.7350 
Length 0.10 0.30 0.7350 
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Table 2.4 Adjusted estimates for the association between maternal TPO status and fetal/infant 
brain and body growth variables 
 
Parameter Estimate SE p-value 
HeadCircumferenceѱ -0.82 0.24 0.0009 
Brain Weightѱ -20.64 6.11 0.0008 
Brain-to-Body Ratio Ϯ -0.49 0.20 0.0143 
Birth Weight Ϯ -0.05 0.06 0.4295 
Abdominal Circumference Ϯ -0.49 0.28 0.0751 
Chest Circumference Ϯ 0.02 0.24 0.9479 
Length Ϯ 0.07 0.27 0.7954 
 
 
ѱAdjusted for maternal race/ethnicity, smoking habits, maternal age, marital status, parity, 
maternal obesity, delivery type, infant gender, infant birth weight and gestational age at delivery. 
Ϯ Adjusted for maternal race/ethnicity, smoking habits, maternal age, marital status, parity, 
maternal obesity, delivery type, infant gender and gestational age. 
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Table 2.5 Adjusted means of fetal/infant brain and body growth variables by maternal TPO 
status 
 
 
Head Circumferenceѱ 
 
TPO+ TPO- 
p- 
value 
CRUDE 34.45 (±0.19) 34.86 (±0.07)  0.0420 
ADJUSTED 34.47 (±0.15) 34.85 (±0.05)  0.0200 
Brain 
Weightѱ 
CRUDE 331.15 (±4.72) 341.45 (±1.66) 0.0398 
ADJUSTED 331.94 (±3.81) 341.32 (±1.31) 0.0204 
 
Brain-to-Body Ratio Ϯ  
CRUDE 9.91 (±0.15) 10.12 (±0.05) 0.1876 
ADJUSTED 9.84 (±0.11) 10.13 (±0.04) 0.0184 
Birth 
Weight Ϯ 
CRUDE 3374.16 (±59.98) 3407.21 (±21.07) 0.6033 
ADJUSTED 3358.88 (±56.36) 3409.46 (±19.79) 0.3982 
 
Length Ϯ 
CRUDE 51.11 (±0.28) 51.02 (±0.10) 0.7517 
ADJUSTED 51.24 (±0.20) 51.00 (±0.07) 0.2752 
 
Abdominal 
Circumference Ϯ 
CRUDE 30.98 (±0.28) 31.35 (±0.10) 0.2094 
ADJUSTED 31.02 (±0.20) 31.35 (±0.07) 0.1214 
 
Chest Circumference Ϯ  
CRUDE 33.24 (±0.25) 33.17 (±0.09) 0.7953 
ADJUSTED 33.31 (0.16) 33.16 (±0.36) 0.3598 
 
 
ѱAdjusted for maternal race/ethnicity, smoking habits, maternal age, marital status, parity, 
maternal obesity, delivery type, infant gender, infant birth weight and gestational age at delivery. 
Ϯ Adjusted for maternal race/ethnicity, smoking habits, maternal age, marital status, parity, 
maternal obesity, delivery type, infant gender and gestational age. 
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CHAPTER THREE 
 
 
Manuscript 2: Influence of maternal thyroid dysfunction on infant growth and 
neurocognitive development 
 
 
The objective of this analysis was to explore the relationship of antenatal thyroid peroxidase 
antibody status (TPO) and maternal postpartum thyroid dysfunction (PPTD) on early infant 
growth and neurocognitive development.  Forty-one (41) mother-infant dyads were recruited 
from a larger, on-going study on trajectories of postpartum thyroiditis. TPO status was 
determined during pregnancy, newborn variables were collected at delivery and infant growth 
assessments were conducted at 3, 4, 5 and 6 months postpartum. Mixed model analysis 
revealed infants of TPO+ mothers were smaller at birth but experienced accelerated growth 
between birth to 3 months as compared to their negative counterparts (head circumference: β = 
1.1983 p=0.0044; weight: β = 1.2757 p = 0.0014; length: β=0.4916 p=0.0351). This acceleration 
led to their catch-up in growth to their TPO negative counterparts by 3 months of age.  No 
significant differences were noted in neurocognitive outcomes between infants born to TPO+ 
mothers compared to those born to TPO- mothers. These exploratory analyses suggest that 
maternal autoantibody status and subsequent postpartum thyroid dysfunction could lead to 
variations in early infant growth and development. The end-result of these variations is unclear. 
Further research is needed to determine the potential impact of reduced head circumference 
and accelerated growth as it relates to long-term neurocognitive consequences. 
Abstract 
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Thyroid dysfunction is one of the most common endocrine disorders in women of childbearing 
age
Introduction 
 
 
(1) and has been linked to numerous adverse pregnancy and birth outcomes ranging from 
miscarriage to preterm delivery(11, 13, 18-20, 89, 90). Documented long-term consequences of 
maternal thyroid dysfunction include delayed learning, lowered IQ and hearing deficits in older 
offspring(14-17). Thyroid dysfunction is detected in 2-3% of pregnant women however; a 
greater percentage of women may be euthyroid but carry the anti-thyroid perioxidase (TPO) 
antibody. Thyroid peroxidase is an enzyme that is instrumental in the synthesis of thyroid 
hormone.  Interruption in the production of thyroid hormones can critically impact brain 
development, growth regulation and metabolism. Approximately 10% of pregnant women are 
TPO positive and the presence of this antibody at higher than normal titers is associated with 
development of postpartum thyroid dysfunction or postpartum thyroiditis (PPT) in up to 50% of 
the women(75, 91). 
 
 
Postpartum thyroiditis has a typical course with the majority of women developing thyroid 
disease during the first 6 months postpartum. Early symptoms of PPT are related to the initial 
hyperthyroid state, which usually occurs between 2 and 6 months after delivery and may last 1 
to 2 months(37). Mild symptoms of hyperthyroidism are present (heat intolerance, palpitations, 
weight loss, fatigue) during this initial stage. The hypothyroid phase typically develops between 
the 12th to 24th weeks after delivery, and the most frequent symptom is depression(47), along 
with the classic symptoms of hypothyroidism. Most women return to a euthyroid stage by 12 
months postpartum(37). 
 
 
Several studies have assessed the effect of abnormal thyroid function during gestation on the 
pregnancy outcome but few have examined the long-term impact of maternal TPO antibody 
29  
status and subsequent postpartum thyroid dysfunction (PPTD) on the offspring (9).  Pop et al 
investigated the impact of maternal thyroid dysfunction and depression during pregnancy and 
during the postpartum period on child development during the preschool years (9). Using the 
McCarthy Scales of Children’s Abilities (MSCA) to assess child development at 5 years of age, 
they did not find a significant difference in scores among preschoolers of mothers who 
experienced PPTD compared to mothers who did not develop PPTD. They did, however, report 
that children of mothers who were TPO positive postpartum or who experienced postpartum 
depression tended to score lower on the MSCA.  Among the study limitations noted by the 
investigators was the assessment of child development five years following delivery.  This 
analysis addresses that limitation by assessing infant development between birth and 6 months 
postpartum. The current study explores the relationship of antenatal thyroid peroxidase 
antibody status and maternal postpartum thyroid dysfunction on early infant growth and 
neurocognitive development by examining the changes in anthropometric measurements and 
developmental milestones over a 6-month time period. 
 
 
This sub-study is embedded in a larger R01 study on trajectories of postpartum thyroiditis 
(referred to as parent grant)(
Methods 
 
92). For the parent grant, pregnant women (N = 631) were 
recruited from prenatal clinics in Tampa, Florida and the surrounding area. Study participants 
were assessed mid-pregnancy (16-24 weeks gestation) and identified as either TPO-positive or 
-negative. Exclusion criteria included the following: younger than age 18 or older than age 45, 
known autoimmune disease, previous thyroid disease, HIV positivity, use of medications that 
affect immunity, chronic diseases, mental illness, body mass index (BMI) <20, history of 
hyperemesis, current multiple gestation, current pregnancy product of in vitro fertilization (IVF), 
fetal abnormalities, unable to understand and speak the recruiter’s language (English or 
Spanish), and being unable to participate in a 6-month postpartum follow-up. All TPO-positive (n 
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= 63) women were invited into the postpartum phase of the study, whereas a convenience 
sample of TPO negative women were selected by a random number generator to participate in 
the postpartum phase (n = 72). All TPO-positive women had TSH measured at time of 
pregnancy testing and at each postpartum visit. Women recruited into the parent grant received 
a monthly home visit by a research nurse for 6 months and a graduated honorarium of $200 for 
completion of 6 months of data collection. 
 
 
Participants 
 
Institutional Review Board approval was obtained and informed consent garnered prior to 
participant enrollment in the parent study and sub-study. Forty-one (41) mother-infant dyads 
were recruited into the sub-study at 3months postpartum and followed until the 6th postpartum 
month. All assessments were conducted in the home environment. 
 
 
Anthropometric Measurements 
 
Newborn anthropometric measurements including birth weight (pounds), birth length (inches), 
and head circumference (cm) were retrieved from maternal delivery records. In the longitudinal 
phase of the study, infants were weighed with a digital portable scale (in pounds) (Unisar Model 
#BR149).  Body length was measured using a transportable Infantometer (in inches) (SECA 416 
Mobile Infantometer).  Additionally, head circumference was measured with a measuring tape  
(in centimeters).   Figure 3.1 depicts the schedule of assessments. 
 
 
Neurocognitive Assessment 
 
Infant neurocognitive function was assessed using the Bayley Scales of Infant Development, 
Third Edition (Bayley-III)(93) Screening Test at 3 months of age. The norm referenced 
screening test assesses cognitive, motor and language skills and can be administered in 15 to 
25 minutes. The test indicates infant development through levels of risk categorized as 
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“Competent”, “Emerging” and “At Risk”. At 6 months of age, infant’s neurocognitive 
characteristics were assessed using the full-scale Bayley-III which includes cognitive, language, 
and motor scales in addition to a social-emotional subtest (authored by Stanley Greenspan, 
MD) and an adaptive behavior subtest (developed by Patti L. Harrison, PhD and Thomas 
Oakland, PhD). The norm referenced Bayley-III has been validated for children ages 1 to 42 
months. Administration of the Bayley-III can range from 30 to 90 minutes depending on the 
child’s age.  All infant assessments were conducted in the home environment. 
 
 
Data Analysis 
 
Background characteristics at baseline (delivery) were compared between TPO+ vs. TPO- and 
PPTD+ vs. PPTD- mothers using the chi-square test or Fisher exact test when appropriate. 
These factors included maternal race/ethnicity, marital status and level of education.  Two 
sample t-tests were used to determine the difference in means for infant weight, length and 
head circumference according to mothers’ TPO and PPTD status. The Bayley-III Screening 
scores were collapsed into two levels and assessed categorically (competent/emerging vs. at- 
risk ). The full Bayley-III has a mean domain score of 100 ± 15. These scores were assessed 
on a continuous scale and mean scores were presented according to mothers’ TPO and PPTD 
status. 
 
Statistical Analysis 
 
 
In the longitudinal phase of this study, outcome information is assessed at several points in  
time. The overall objective is to characterize the changes in the outcome(s) (e.g., infant weight, 
length and head circumference) over time and to assess the influence of maternal TPO status 
on infant growth patterns. Dependence exists between the repeated measurements taken within 
the same subject. Therefore, the observations for each individual will be correlated and thus, 
violate the independence assumption that is required for most conventional fixed effect 
32  
methods. Mixed models provide a flexible approach to correlated data such as these by 
incorporating both fixed and random effects in the same analysis(94). This approach models 
the means and the residuals around the mean. Fixed effects correspond to the means, which 
does not vary across individual subjects, whereas random effects model the residuals, which 
vary across subjects and are random deviations in the relationships described by the fixed 
effects(94). 
 
 
In analysis of repeated measures, selection of the most appropriate covariance structure is 
critical in order to form accurate conclusions(95). As the analysis of the longitudinal data was 
modeled over the course of 5 visits (birth to 6 months) and subsequently analyzed from 3 
months to 6 months (4 visits), several covariance patterns were tested for each analysis. The 
Akaike information criteria (AIC)(96) and the Bayesian information criterion (BIC)(97) were used 
to assess the goodness of fit(94) for each covariance structure (see Table B.1 in Appendix B). 
The “best” fitting model was based on those with lowest AIC and BIC values. Based on 
goodness of fit, the first order ante dependence (ANTE(1)) covariance pattern was selected for 
analysis of data from birth to 6 months (5 visits). The covariance structure was deemed most 
appropriate because there was a gap in assessments from birth to 3 months followed by 
monthly assessments from 3 months to 6 months and the first order ante dependence 
covariance structure allows for unequal visit spacing and changes in the correlation structure 
over time. The first order autoregressive (AR(1))covariance pattern was selected for the 3 to 6 
months (4 visits) sub-analysis of evenly spaced assessments. In the AR(1) covariance model, 
the variances are the same for all visits and the covariance decreases exponentially. Due to the 
curvilinear nature of infant growth as depicted in Figures 3.2-3.7, a quadratic term was tested in 
the fit of each mixed model. Tables B.2 and B.3 in Appendix B provide additional information on 
model fit. 
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Figures 3.2, 3.3, and 3.4 illustrate mean growth of infant head circumference, infant weight, and 
infant length, respectively, from 3 to 6 months. Figure 3.2 depicts infants born to TPO+ women 
appear to have a smaller head circumference at the 3 months and the trend remained until 6 
Results 
 
Forty-one infant-mother dyads were enrolled in the supplemental project. Complete 
anthropometric and neurocognitive measurements, assessed over 5 time points, were collected 
on 37 of the 41 infants (90%). Two of infant-mother dyads only had information for 4 time points 
(baseline and 3 follow-up visits) and 2 of the infant-mother dyads only had information for 3 time 
points (baseline and 2 follow-up visits). Of the infants enrolled, 53.66% (n=22) were born to 
mothers who were TPO+ during pregnancy. Table 3.1 depicts selected socio-demographic 
characteristics by maternal TPO status. TPO+ mothers were more likely to be older in age, 
White Non-Hispanic, and have greater than a high school education.  Infants born to TPO+ 
mothers tended to weigh a little less than those born to TPO- mothers and to have a  
significantly smaller head circumference at birth (34.00 (±1.51) vs. 35.41 (±1.83), respectively). 
Gestational age at delivery and birth length did not differ significantly among the maternal 
groups (Table 3.2). 
 
 
Nearly 55% (n=12) of the TPO+ mothers subsequently developed postpartum thyroid 
dysfunction (PPTD). TPO+ mothers who developed postpartum thyroid dysfunction were more 
likely be overweight or obese pre-pregnancy and during the postpartum period (Table 3.3). 
Infants born to mothers who subsequently developed postpartum thyroiditis were more likely to 
have a smaller head size at birth (Table 3.4). No significant differences were noted infant in 
birth weight or birth length. Tables 3.5 and 3.6 depict the mean infant growth variables by 
maternal TPO and PPT status, respectively. 
 
 
Infant growth – Birth to 6 months 
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months of age. Infants born to TPO+ mothers weighed less at birth but appeared to surpass 
their negative counterparts prior to 3 months of age and subsequently exhibit similar mean 
weight to their TPO- counterparts at 6months of age (Figure 3.3). Little differences were noted 
in infant length (Figure 3.4). 
 
 
Table 3.7 presents the mixed models analysis results from birth to 6 months of age. The  
variable Time depicts the increase in growth of infant as they age from birth to 6 months and the 
Time*Time variable indicates that infant growth decelerates as the infant ages.  Similar to the 
trajectories depicted in Figures 3.2 and 3.3, results of the mixed models analysis suggest 
thatinfants born to TPO+ mothersexperience accelerated growth in head circumference and 
weightcompared to infants born to TPO-mothers (Table 3.7).  However, the acceleration is not 
sustained throughout the entire 6 month timeframe. At some point in time, infants born to TPO+ 
mothers “catch-up” to their TPO- counterparts and their growth trajectory becomes 
indistinguishable from that of infants born to TPO- mothers. The adjusted means, presented in 
Table 3.5 further illustrate that infants born to TPO+ mothers have a smaller mean head 
circumference at birth and subsequently surpass their TPO- counterparts by 3 months of age; 
however by 5 months of age there is no significant difference between the two groups. Analysis 
of infant growth between 3 to 6 months age (Table 3.8) did not reveal any significant differences 
in the growth trajectory of the two groups. 
 
 
In this study sample, more than half of the TPO+ mothers subsequently developed thyroid 
dysfunction. An exploratory analysis was conducted to examine the outcomes of infants born to 
TPO+ mothers who did not develop postpartum thyroid dysfunction (TPO+ only) and the 
outcomes of infants born to TPO+ mothers who experienced postpartum thyroid dysfunction 
(PPTD) as compared to infants born to TPO- mothers. Figures 3.5-3.7 illustrate the growth 
trajectories of infant by maternal PPTD status.  Tables 3.8 and 3.9 depict mixed methods 
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analysis results for birth to 6 months and 3 to 6 months, respectively. No significant differences 
were noted in the growth of infants whose mothers subsequently developed PPTD as compared 
to their negative counterparts (Table 3.8). 
 
 
Similar analysis was conducted to assess the influence of maternal TPO and/or PPTD status on 
infant neurocognitive development. Tables 3.11 and 3.12 depict the percentage of infants who 
screened “at risk” by maternal TPO or PPTD status.  No significant differences were noted 
between groups in the five (5) developmental areas assessed (cognitive, expressive 
communication, receptive communication, fine motor and gross motor skills).  Nor were 
statistical differences seen in the mean neurodevelopmental scores obtained from the Bayley-III 
assessment conducted at 6 months of age (Table 3.13). 
 
 
Thyroid hormones are critical for infant brain and body development, as they regulate the 
processes of dendritic and axonal growth, neuronal migration, and myelination in addition to 
growth hormone. In the early stages of pregnancy the fetus relies solely on the proper 
functioning of the mother’s thyroid and thus the subsequent hormone supply.  Previous research 
indicates that overt maternal dysfunction during pregnancy can have lasting effects on the 
mother and infant, however; literature regarding the influence of thyroid autoantibody status in 
the presence of euthyroidism is scarce. Additionally, a paucity of research exists on the 
potential impact of maternal postpartum thyroid dysfunction on infant outcomes. Results of this 
analysis demonstrated that infants born to TPO+ mothers have a smaller head circumference 
and weigh less at birth but essentially catch-up in growth between 3 to 6 months of age. The 
birth to 3 month timeframe appears to be the most significant period for catch-up growth for 
infants of TPO+ mothers. 
Discussion 
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Results of this analysis suggest that the influence of maternal TPO status on infant 
anthropometric outcomes is influenced by maternal/race ethnicity. However, the limited sample 
size restricted the ability of further meaningful analysis to explore these differences. Future 
studies with larger sample sizes are indicated to confirm these results and explore the 
relationships in-depth.  Additionally, epigenetic studies may be warranted to identify any genetic 
variants or single nucleotide polymorphisms (SNPs), which could elucidate the interaction 
between maternal TPO status and race/ethnicity. 
 
 
It was determined that a minimum of 123 women (82 TPO+ and 41 TPO-) were required to 
detect a 5 point difference in the Bayley-III scoreswith a type I error of 0.05 and type II error of 
0.20. Analyses of differences in neurocognitive outcomes were underpowered due to the 
smaller than expected sample size. Although this analysis was under-powered to detect any 
differences in neurocognitive outcomes, previous studies which have examined maternal thyroid 
status and neurocognitive outcomes of the offspring have detected significant differences. Li et 
al.(98)conducted a retrospective matched analysis of thyroid function among 213 women (71 
cases and 142 controls) between 16-20 weeks of gestation to examine the impact of subclinical 
hypothyroidism, hypothyroxinaemia and elevated TPO antibody titers on the neurocognitive 
development of offspring between 25-30 months of age. The Bayley Scale of Infant 
Development (BSID I) was used to conduct intellectual and motor evaluations. The authors 
determined offspring of women with subclinical hypothyroidism, hypothyroxinemia and elevated 
TPOAb antibody titers had mean intelligence scores 8.88, 9.30 and 10.56 points lower than 
those of the control group (P = 0.008, P = 0.004 and P = 0.001, respectively); mean motor 
scores were 9.98, 7.57 and 9.03 points lower than those of the controls [P < 0.001, P = 0.007 
and P < 0.001, respectively (t-test)].  Unconditional  multivariate logistic regression analysis 
showed that increased elevated maternal TPO antibody titers were separately associated with 
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lower intelligence scores (OR = 6.69) and poorer motor scores (OR=8.25). Therefore, the 
neurocognitive aspect of this analysis warrants further investigation with a larger sample size. 
 
 
It has been proposed that the presence of anti-TPO antibodies suggest a developing or 
underlying thyroid dysfunction (13, 99).  The presence of thyroid autoantibodies in women with 
normal thyroid function could be associated with a subtle deficiency in the availability of thyroid 
hormones (e.g., a decrease in circulating thyroid hormones within the reference range) or a 
lower capacity of the thyroid gland to adequately meet the demand for the production of thyroid 
hormones required in pregnancy(81, 99). This can have a direct adverse effect on placental or 
fetal development(81, 99). Additionally, thyroid autoantibodies might be an indicator of an 
underlying autoimmune thyroid disorder. 
 
 
There are a few avenues to consider regarding the feasibility of maternal TPO status during 
pregnancy influencing the rate of infant growth during the postpartum period.  Biologically, one 
consideration is the transfer of maternal TPO autoantibodies to the infant. Thyroid 
autoantibodies substantially contribute to the pathogenesis of several thyroid disorders because 
they attack the thyroid gland and disrupt its function (38). Previously published reports have 
determined that maternal TPO autoantibodies cross the placenta.  (10, 24, 100) Therefore, a 
mother’s autoantibody status is reflective of the infant’s autoantibody status(100). A study by 
Kvetny&Hedvig(39) describes a congenital transient hyperthyroidism in neonates of mothers 
with raised levels of thyroid peroxidase autoantibodies during pregnancy. They hypothesize  
that these autoantibodies produce a cytotoxic effect on the neonate thyroid and because brain 
growth and development extends beyond the neonatal period, this transient hyperthyroidism 
has the potential to impair subsequent development of the infant. In the same fashion that 
maternal thyroid peroxidase (TPO) antibodies cross the placenta and attack the fetal thyroid 
gland, a similar situation may occur through the transfer of maternal autoantibodies in breast 
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milk. A study by Tornhage&Grankvist(40) reported that TSH-receptor antibody (TRAb) positive 
mothers may cause transient neonatal thyroid disease in the infant and this condition may be 
worsened and more prolonged as a consequence of TRAb in breast milk. 
 
 
This study benefits from the prospective, laboratory confirmed assessment of maternal TPO 
status and the repeated measurement of infant growth values.  The use of mixed models 
maximized the potential of the data by allowing all available observations to be utilized in the 
analysis.  As this study was conducted within an on-going R01 grant, recruitment of subjects 
was restricted to those who were enrolled in the “parent” grant thus creating a smaller pool of 
available participants. The limited sample size reduced the power of some of the analysis and 
restricted the ability to adequately explore several areas of interest, including the influence of 
various potential confounders (e.g., breastfeeding habits, maternal obesity, maternal education, 
etc) on the relationship between TPO and/or PPTD status on infant outcomes. In addition, this 
study did not have enough power to sufficiently assess the influence of maternal TPO or PPTD 
status on infant neurocognitive outcomes. A larger, prospective study is needed to expound on 
the exploratory results obtained in this analysis. 
 
 
Results of this analysis revealed that infants born to mothers who were TPO positive during 
pregnancy were more likely to have a smaller head circumference at birth and showed 
accelerated growth between birth and 3 months of age; thus suggesting that meaningful 
differences may exist among infants of mothers who have the marker for thyroid dysfunction 
(TPO positivity).  These analyses and previously published reports have provided evidence that 
maternal autoantibody status could lead to variations in infant growth and development 
postpartum (39, 40). The end-result of these variations is unclear. Future research should focus 
on determining the potential impact of reduced head circumference and accelerated growth as it 
relates to long-term neurocognitive outcomes. 
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Figure 3.1 Timeline of infant assessments 
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Table 3.1 Selected socio-demographic characteristics by TPO status (n=41) 
 
 TPO positive 
(N=22) 
TPO negative 
(N=19) 
 
P-value 
Maternal Age 
Mean ± SD 
 
30.6±6.1 
 
27.1±6.5 
 
0.08 
Race/Ethnicity  
14 (63.6%) 
 
8(42.1%) 
 
0.29 White 
Black 4 (18.2%) 4 (21.1%) 
Hispanic 2 (9.1%) 6 (31.6%) 
Other 2 (9.1%) 1 (5.3%) 
Married 
Yes 
 
16 (72.7%) 
 
10 (52.6%) 
 
0.18 
Parity 
Nulliparous 
 
13 (59.1%) 
 
9 (47.4%) 
 
0.45 
Prenatal Smoking 
Yes 
 
1 (4.55%) 
 
2 (10.5%) 
 
0.58 
Breastfeeding  
7 (31.8%) 
 
2 (10.5%) 
 
.22 Exclusive 
Partial 12 (54.6%) 12 (63.2%) 
Never 3 (13.6%) 5 (26.3%) 
Pre-pregnancy BMI 
Overweight/Obese 
 
14 (63.6%) 
 
11 (57.9%) 
 
0.76 
Postpartum BMI 
Overweight/Obese 
 
14 (63.6%) 
 
14 (73.7%) 
 
0.52 
Maternal Education 
>High School 
 
18 (81.8%) 
 
11 (57.9%) 
 
.17 
Postpartum Thyroiditis 
Yes 
 
12 (54.6%) 
 
0 (0.0) 
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Table 3.2 Selected delivery/infant characteristics by maternal TPO status (n=41) 
 
 TPO positive 
N=22 
TPO negative 
N=19 
 
P-value 
Gestational Age at Delivery 
Mean (± SD) 
 
38.8±0.9 
 
38.95±1.1 
 
0.57 
Delivery Type 
Vaginal 
 
13 (59.1%) 
 
10 (52.6%) 
 
0.68 
Gender 
Male 
 
9 (40.9%) 
 
10 (52.6%) 
 
0.45 
1 Minute Apgar 
Apgar < 7 
 
3 (13.6%) 
 
1 (5.3%) 
 
0.61 
Birth Weight (pounds) 
mean (± SD) 
 
7.5 (±0.9) 
 
7.9 (±0.9) 
 
0.14 
Birth Length (inches) 
mean (± SD) 
 
20.3 (±0.2) 
 
20.4 (±2.2) 
 
0.78 
Head Circumference (cm) 
mean (± SD) 
 
34.0 (±1.5) 
 
35.4 (±1.8) 
 
0.01 
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Table 3.3 Selected socio-demographic characteristics by PPTD status (among TPO+ women) 
(n=22) 
 
 PPTD positive 
(N=12) 
PPTD negative 
(N=10) 
 
P-value 
Maternal Age 
Mean ± SD 
 
29.7±5.1 
 
31.8±7.3 
 
0.44 
Race/Ethnicity 
White 
Black 
Hispanic 
Other 
 
8 (66.7%) 
4 (33.3%) 
0 (0.0) 
0 (0.0) 
 
6 (60.0%) 
0 (0.0) 
2 (20.0%) 
2 (20.0%) 
 
0.04 
Married 
Yes 
 
10 (83.3%) 
 
6 (60.0%) 
 
0.34 
Parity 
Nulliparous 
 
9 (75.0%) 
 
4 (40.0%) 
 
0.19 
Prenatal Smoking 
Yes 
 
0 (0.0) 
 
1 (10.0%) 
 
0.45 
Breastfeeding  
4 (33.3%) 
 
3 (30.0%) 
 
0.73 Exclusive 
Partial 7 (58.3%) 5 (50.0%) 
Never 1 (8.3%) 2 (20.0%) 
Pre-pregnancy BMI 
Overweight/Obese 
 
9 (75.0%) 
 
5 (50.0%) 
 
0.38 
Postpartum BMI 
Overweight/Obese 
 
10 (83.3%) 
 
4 (40.0%) 
 
0.07 
Maternal Education 
>High School 
 
9 (75.0%) 
 
9 (90.0%) 
 
0.59 
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Table 3.4 Selected delivery/infant characteristics by PPTD status (among TPO+ women) (n=22) 
 
 PPTD positive 
N=12 
PPTD negative 
N=10 
 
P-value 
Gestational Age at Delivery 
Mean (± SD) 
 
38.9±0.7 
 
38.9±1.1 
 
0.41 
Delivery Type 
Vaginal 
 
9 (75.0%) 
 
4 (40.0%) 
 
0.19 
Gender 
Male 
 
9 (40.9%) 
 
10 (52.6%) 
 
0.45 
1 Minute Apgar 
Apgar < 7 
 
1 (8.3%) 
 
2 (20.0%) 
 
0.57 
Birth Weight (pounds) 
mean (± SD) 
 
7.4 (±1.1) 
 
7.5 (±0.8) 
 
0.79 
Birth Length (inches) 
mean (± SD) 
 
20.4 (±1.0) 
 
20.2 (±0.8) 
 
0.73 
Head Circumference (cm) 
mean (± SD) 
 
33.5 (±1.4) 
 
34.6 (±1.5) 
 
0.09 
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Table 3.5 Mean infant growth variables by maternal TPO status, birth to 6 months 
 
HEAD CIRCUMFERENCE WEIGHT LENGTH 
 TPO+ TPO- p-value TPO+ TPO- p-value TPO+ TPO- p-value 
34.00 35.42 0.0097 7.45 7.89 0.1407 20.31 20.39 0.7769 
 CRUDE (±0.36) (±0.38)  (±0.20) (±0.21)  (±0.19) (±0.20)  
BIRTH           
 ADJUSTED 34.18 35.21 0.0354 7.44 7.90 0.1479 20.33 20.36 0.9141 
  (±0.30) (±0.33)  (±0.20) (±0.22)  (±0.19) (±0.21)  
  41.12 41.39 0.3793 14.61 14.32 0.5656 24.40 24.24 0.5825 
 CRUDE (±0.21) (±0.23)  (±0.34) (±0.37)  (±0.20) (±0.21)  
3 MONTHS 
ADJUSTED 41.50 40.95 0.0187 14.96 13.92 0.0167 24.49 24.13 0.0992 
 (±0.14) (±0.15)  (±0.27) (±0.29)  (±0.14) (±0.15)  
 42.19 42.35 0.6292 15.96 15.50 0.4046 25.26 25.17 0.7563 
CRUDE (±0.22) (±0.24)  (±0.37) (±0.40)  (±0.20) (±0.21)  
4 MONTHS 
ADJUSTED 42.55 41.92 0.0376 16.28 15.13 0.0260 25.34 25.08 0.2661 
 (±0.18) (±0.20)  (±0.32) (±0.35)  (±0.15) (±0.17)  
 43.02 43.57 0.0967 16.81 16.91 0.8482 25.92 25.90 0.9483 
CRUDE (±0.22) (±0.24)  (±0.35) (±0.39)  (±0.20) (±0.22)  
5 MONTHS 
ADJUSTED 43.37 43.13 0.4464 17.09 16.56 0.2863 26.01 25.78 0.3872 
 (±0.19) (±0.21)  (±0.31) (±0.34)  (±0.17) (±0.19)  
 43.87 44.23 0.2863 18.03 18.13 0.8634 26.72 26.66 0.8585 
CRUDE (±0.22) (±0.25)  (±0.40) (±0.47)  (±0.24) (±0.28)  
6 MONTHS 
ADJUSTED 44.18 43.82 0.2349 18.33 17.72 0.3009 26.82 26.51 0.3414 
 (±0.17) (±0.21)  (±0.36) (±0.42)  (±0.20) (±0.24)  
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Table 3.6 Mean infant growth variables by maternal PPTD status, birth to 6 months 
 
HEAD CIRCUMFERENCE WEIGHT LENGTH 
 PPTD+ PPTD- p-value PPTD+ PPTD- p-value PPTD+ PPTD- p-value 
33.50 34.60 0.0893 7.41 7.51 0.7991 20.37 20.23 0.7271 
 CRUDE (±0.42) (±0.45)  (±0.27) (±0.30)  (±0.26) (±0.29)  
BIRTH           
 ADJUSTED 33.74 34.31 0.3290 7.56 7.33 0.5801 20.52 20.06 0.2784 
  (±0.37) (±0.41)  (±0.26) (±0.28)  (±0.26) (±0.29)  
  40.88 41.40 0.1078 14.01 15.33 0.1117 24.35 24.45 0.8381 
 CRUDE (±0.21) (±0.23)  (±0.53) (±0.58)  (±0.31) (±0.34)  
3 MONTHS 
ADJUSTED 41.12 41.11 0.9726 14.19 15.12 0.1303 24.49 24.29 0.6051 
 (±0.15) (±0.16)  (±0.37) (±0.41)  (±0.24) (±0.27)  
 41.99 42.42 0.2703 15.42 16.61 0.1628 25.31 25.20 0.8209 
CRUDE (±0.25) (±0.28)  (±0.55) (±0.60)  (±0.33) (±0.36)  
4 MONTHS 
ADJUSTED 42.20 42.17 0.9232 15.62 16.37 0.3020 25.46 25.03 0.3095 
 (±0.24) (±0.27)  (±0.45) (±0.49)  (±0.29) (±0.29)  
 42.84 43.25 0.2302 16.39 17.37 0.2035 25.95 25.87 0.8744 
CRUDE (±0.22) (±0.25)  (±0.49) (±0.57)  (±0.30) (±0.34)  
5 MONTHS 
ADJUSTED 42.97 43.08 0.7288 16.51 17.21 0.2631 26.11 25.65 0.2691 
 (±0.20) (±0.24)  (±0.37) (±0.44)  (±0.25) (±0.29)  
 43.66 44.13 0.2385 17.31 18.88 0.0865 26.59 26.88 0.6212 
CRUDE (±0.26) (±0.29)  (±0.56) (±0.64)  (±0.38) (±0.41)  
6 MONTHS 
ADJUSTED 43.88 43.87 0.9874 17.58 18.56 0.2048 26.86 26.55 0.5722 
 (±0.26) (±0.29)  (±0.47) (±0.52)  (±0.33) (±0.37)  
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Figure 3.2 Mean head circumference by maternal TPO status, birth to 6 months 
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Figure 3.3 Mean weightby maternal TPO status,birth to 6 months 
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Figure 3.4 Mean infant lengthby maternal TPO status,birth to 6 months 
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Table 3.7 Influence of maternal TPO status on infant growth from birth to 6 months 
 
Birth to 6 months 
205 observations 
Basic 
β 
 
p-value 
Adjusted† 
β 
 
p-value 
Head Circumference     
TPO -1.3595 0.0119 -1.1069 0.0358 
TIME 2.4614 <.0001 2.9859 <.0001 
TIME*TIME -0.1684 <.0001 -0.2268 <.0001 
TPO*TIME 0.5261 0.0068 0.5225 0.0085 
TPO*TIME*TIME -0.0578 0.0290 -0.0568 00311 
Weight     
TPO -0.4398 0.1440 -0.1007 0.9221 
TIME 2.8721 <.0001 2.9184 <.0001 
TIME*TIME -0.1868 <.0001 -0.1918 <.0001 
TPO*TIME 0.4366 0.0510 0.4386 0.0549 
TPO*TIME*TIME -0.0600 0.0443 -0.0604 0.0440 
Length     
TPO -0.0909 0.7636 0.1890 0.5316 
TIME 1.6259 <.0001 1.5107 <.0001 
TIME*TIME -0.0920 <.0001 -0.0786 <.0001 
TPO*TIME 0.1146 0.3042 0.1148 0.3072 
TPO*TIME*TIME -0.0133 0.5188 -0.0135 0.5143 
†Models adjusted for maternal race/ethnicity, maternal age, and infant gender. 
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Table 3.8 Influence of maternal TPO status on infant growth from 3 to 6 months 
 
3 months to 6 months 
164 observations 
Basic 
β 
 
p-value 
Adjusted† 
β 
 
p-value 
Head Circumference     
TPO -0.2478 0.6536 0.3188 0.5156 
TIME 0.9180 <.0001 0.9171 <.0001 
TPO*TIME -0.0097 0.9279 0.0005 0.9962 
Weight     
TPO 0.5920 0.3104 1.5618 0.0018 
TIME 1.1382 <.0001 1.1378 <.0001 
TPO*TIME 0.0880 0.3623 -0.0887 0.3566 
Length     
TPO 0.1962 0.6249 0.5042 0.0945 
TIME 0.7734 <.0001 0.7701 <.0001 
TPO*TIME -0.0143 0.8325 -0.0091 0.9039 
†Models adjusted for variable at birth (e.g., head circumference at birth, birth weight or birth 
length), maternal race/ethnicity, maternal age, and infant gender. 
52  
M
ea
n 
He
ad
 C
irc
um
fe
re
nc
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age (Months) 
 
 
Figure 3.5 Mean head circumference by maternal PPTD status, birth to 6 months 
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Figure 3.6 Mean infant weight by maternal PPTD status, birth to 6 months 
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Figure 3.7 Mean infant length by maternal PPTD status, birth to 6 months 
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Table 3.9 Influence of maternal PPTD status on infant growth from birth to 6 months 
 
Birth to 6 months 
110 observations 
Basic 
β 
 
p-value 
Adjusted† 
β 
 
p-value 
Head Circumference     
PPTD -1.1063 0.0778 -0.5640 0.3806 
TIME 2.8331 <.0001 2.8441 <.0001 
TIME*TIME -0.2117 <.0001 -0.2169 <.0001 
PPTD*TIME 0.2839 0.2843 0.2826 0.3038 
PPTD*TIME*TIME -0.0299 0.4254 -0.0296 0.4175 
Weight     
PPTD -0.1034 0.8061 1.1641 0.0211 
TIME 2.9150 <.0001 2.9054 <.0001 
TIME*TIME -0.1867 <.0001 -0.1856 <.0001 
PPTD*TIME -0.3194 0.3570 -0.3324 0.3370 
PPTD*TIME*TIME -0.01781 0.6659 0.0191 0.6464 
Length     
PPTD 0.1867 0.6972 1.0721 0.0462 
TIME 1.6468 <.0001 1.6450 <.0001 
TIME*TIME -0.0881 <.0001 -0.0882 <.0001 
PPTD*TIME -0.0376 0.8170 0.0359 0.8277 
PPTD*TIME*TIME -0.0070 0.0298 -0.0070 0.8139 
†Models adjusted for maternal race/ethnicity, maternal age, and infant gender. 
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Table 3.10 Influence of maternal PPTD status on infant growth from 3 to 6 months 
 
3 months to 6 months 
88 observations 
Basic 
β 
 
p-value 
Adjusted† 
β 
 
p-value 
Head Circumference     
PPTD -0.5371 0.3019 -0.0838 0.8624 
TIME 0.9050 <.0001 0.9042 <.0001 
PPTD*TIME 0.0158 0.8844 0.0158 0.8904 
Weight     
PPTD -1.0562 0.2843 -0.5674 0.4968 
TIME 1.1847 <.0001 1.1847 <.0001 
PPTD*TIME -0.0844 0.4614 -0.0845 0.4546 
Length     
PPTD 0.1243 0.8469 0.4689 0.3337 
TIME 0.8082 <.0001 0.8076 <.0001 
PPTD*TIME -0.0622 0.6499 -0.0655 0.5766 
†Models adjusted for variable at birth (e.g., head circumference at birth, birth weight or birth 
length), maternal race/ethnicity, maternal age, and infant gender. 
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Table 3.11 Percentage of “at-risk” infants by maternal TPO status 
 
Screening – 3 months At Risk 
n (%) 
 
p-value 
Cognitive   
TPO+ 3(12.6) 0.2354 
TPO- 0 (0.0) 
Expressive Communication   
TPO+ 0 (0.0)  
TPO- 0 (0.0) 
Receptive Communication   
TPO+ 6 (27.3) 0.4659 
TPO- 3 (15.8) 
Fine Motor   
TPO+ 1 (4.6)  
TPO- 0 (0.0) 
Gross Motor   
TPO+ 0 (0.0)  
TPO- 0 (0.0) 
58  
Table 3.12 Percentage of “at-risk” infants by maternal TPO and PPTD status 
 
Screening – 3 months At Risk 
n (%) 
 
p-value 
Cognitive   
PPTD 2 (16.7) 0.2148 
TPO+ 1 (10.0) 
TPO- 0 (0.0) 
Expressive 
Communication 
  
PPTD 0 (0.0)  
TPO+ 0 (0.0) 
TPO- 0 (0.0) 
Receptive 
Communication 
  
PPTD 3 (25.0) 0.6560 
TPO+ 3 (30.0) 
TPO- 3 (15.8) 
Fine Motor   
PPTD 1 (8.3)  
TPO+ 0 (0.0) 
TPO- 0 (0.0) 
Gross Motor   
PPTD 0 (0.0)  
TPO+ 0 (0.0) 
TPO- 0 (0.0) 
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Table 3.13 Mean Bayley-III scores by maternal TPO status 
 
 TPO + (N=22) 
Mean (±SD) 
TPO - (N=16) 
Mean (±SD) 
P- 
value 
Cognitive 88.9 90.1 0.68 
(±7.4) (±10.6) 
Language 82.5 82.9 0.90 
(±9.7) (±9.5) 
Motor 94.9 98.3 0.40 
(±11.3) (±13.0) 
Socio-Emotional 106.1 110.0 0.40 
(±15.1) (±12.0) 
Adaptive Behavior 96.1 98.9 0.37 
(±10.2) (±7.9) 
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Table 3.14 Mean Bayley-III scores by maternal PPTD and TPO status 
 
 PPTD (N=12) 
Mean (±SD) 
TPO + (N=10) 
Mean (±SD) 
TPO - (N=16) 
Mean (±SD) 
P-value 
Cognitive 89.2 88.5 90.1 0.91 
(±7.0) (±8.2) (±10.6) 
Language 79.7 85.9 82.9 0.33 
(±10.2) (±8.5) (±9.5) 
Motor 96.3 93.3 98.3 0.60 
(±11.7) (±11.1) (±13.0) 
Socio-Emotional 105.0 107.5 110.0 0.65 
(±14.9) (±16.0) (±12.0) 
Adaptive Behavior 96.7 95.4 98.9 0.64 
(±8.4) (±12.4) (±7.9) 
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CHAPTER FOUR 
 
Conclusions and Recommendations 
 
The findings of this research indicate that TPO positivity is associated with reduced brain growth 
measurements at delivery; however, the relationship appears to be modified by maternal 
race/ethnicity. The difference in brain growth measurements may be more noticeable among the 
White non-Hispanic racial/ethnic group because they are more likely than their non-white 
counterparts to deliver later term, thus allowing the differences in brain growth variables to be 
more apparent. Whereas, non-white mothers have a tendency to deliver earlier term infants  
who may not have had the opportunity to reach full potential, thereby masking the effects of  
TPO influence. Significant differences were not observed in other anthropometric  
measurements (e.g., birth weight, birth length). 
 
 
Results of this dissertation also demonstrated that infants born to TPO+ mothers have a smaller 
head circumference and weigh less at birth but essentially catch-up in growth between 3 to 6 
months of age. The birth to 3 month timeframe appeared to be the most significant period for 
catch-up growth for infants of TPO+ mothers.  Exploratory analyses suggested that TPO 
positivity and subsequent postpartum thyroid dysfunction may be considered on a continuum in 
regards to certain infant growth measurements, as the impact of reduced head circumference 
and accelerated catch-up growth was more significant among infants born to mothers who 
developed postpartum thyroid dysfunction as compared to infants born to mothers who were 
TPO+ only. This analysis was under-powered to detect any differences in neurocognitive 
outcomes of infants. 
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Future studies with larger sample sizes are indicated to confirm the results obtained in this 
dissertation, particularly those results that did not quite reach statistical significance. For 
instance, this analysis suggested that antenatal TPO positivity may result in reduced infant 
abdominal circumference (β = -0.380 (SE = 0.210; p<.08)). This finding is worthy of further 
investigation, as reduced abdominal circumference measurements are indicative of impaired 
fetal liver growth in utero, which may impact postpartum infant growth. Additionally, future 
research should employ a larger sample size to explore more in-depth the influence of various 
potential confounders (e.g., breastfeeding habits, maternal obesity, maternal education, etc) on 
the relationship between TPO and/or PPTD status on infant outcomes. 
 
 
Epigenetic studies may be warranted to identify any genetic variants or single nucleotide 
polymorphisms (SNPs), which could elucidate the interaction between maternal TPO status and 
race/ethnicity.  Epigenetic analysis may prompt ethnic-based screening for TPO autoantibodies. 
Considering the long-term implications of impaired fetal/newborn growth, it is important to 
identify avenues for early prevention and intervention.  Maternal thyroid antibody status during 
pregnancy may be one of those factors that play a role in fetal growth impairment but is 
currently being overlooked due to lack of consensus on maternal testing and treatment.  At 
present, TPO antibody status is not assessed as part of the standard prenatal care laboratory 
work-up, but this study suggests that fetal brain growth may be impaired by TPO positivity 
among certain populations, therefore, autoantibody screening among high-risk sub-groups may 
be useful for clinicians to determine whether prenatal thyroid treatment is warranted. Future 
research should also focus on determining the potential impact of reduced head circumference 
and accelerated growth as it relates to long-term neurocognitive outcomes. 
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APPENDIX A: SUPPLEMENTAL MATERIAL FOR MANUSCRIPT 1 
 
 
Figure A.1Fit diagnostics for fetal/infant head circumference model (predictor variables include 
maternal TPO status, maternal race/ethnicity, maternal age, marital status, smoking habits, 
parity, obesity risk, delivery type, gender of the infant, infant birth weight and gestational age at 
delivery). 
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Figure A.2Fit diagnostics for fetal/infant brain weight model (predictor variables include maternal 
TPO status, maternal race/ethnicity, maternal age, marital status, smoking habits, parity, obesity 
risk, delivery type, gender of the infant, infant birth weight and gestational age at delivery). 
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Figure A.3 Fit diagnostics for fetal/infant brain-body-ratio model (predictor variables include 
maternal TPO status, maternal race/ethnicity, maternal age, marital status, smoking habits, 
parity, obesity risk, delivery type, gender of the infant, and gestational age at delivery). 
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Figure A.4Fit diagnostics for infant birth weight model (predictor variables include maternal TPO 
status, maternal race/ethnicity, maternal age, marital status, smoking habits, parity, obesity risk, 
delivery type, gender of the infant and infant birth length). 
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Figure A.5Fit diagnostics for infant birth length model (predictor variables include maternal TPO 
status, maternal race/ethnicity, maternal age, marital status, smoking habits, parity, obesity risk, 
delivery type, gender of the infant, infant birth weight and gestational age at delivery). 
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Abdominal Circumference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.6Fit diagnostics for abdominal circumference model (predictor variables include 
maternal TPO status, maternal race/ethnicity, maternal age, marital status, smoking habits, 
parity, obesity risk, delivery type, gender of the infant, infant birth weight and gestational age at 
delivery). 
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Figure A.7 Fit diagnostics for chest circumference model (predictor variables include maternal 
TPO status, maternal race/ethnicity, maternal age, marital status, smoking habits, parity, obesity 
risk, delivery type, gender of the infant, infant birth weight and gestational age at delivery). 
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Table A.1 Pearson correlation coefficients for fetal/infant brain and body growth variables 
 
Pearson Correlation Coefficients 
Prob> |r| under H0: Rho=0 
Number of Observations 
HEAD BRA_WT BBR WGHT LNGTH  ABD CHST 
HEAD 1.0000  0.999 0.25284 0.57159 0.38532 0.45194 0.48092 
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
528 528 528 528 528 522 524 
 
 
BRA_WT 0.999 1.0000 0.25217 0.57215 0.38382 0.45029 0.47948 
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
528 528 528 528 528 522 524 
 
 
BBR 0.2528 0.2522 1.0000 -0.6389 -0.4377 -0.4079 -0.4606 
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
528 528 528 528 528 522 524 
 
 
WGHT 0.5716 0.5722 
- 
0.63892 1.0000 0.67121 0.69718 0.7697 
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
528 528 528 528 528 522 524 
 
 
LNGTH 0.3853 0.3838 
- 
0.43765 0.67121 1.0000 0.42574 0.4997 
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
528 528 528 528 528 522 524 
 
 
ABD 0.4519 0.4503 
- 
0.40794 0.69718 0.42574 1.0000 0.74371 
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
522 522 522 522 522 522 522 
 
 
CHST 0.4809 0.4795 
- 
0.46063 0.7697 0.4997 0.74371 1.0000 
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
524 524 524 524 524 522 524 
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Table A.2 Mean gestational age at delivery by maternal race/ethnicity and TPO status 
 
  
n Mean (±SD) 
 
P-value 
White 253 39.15 (1.06)  
 
TPO+ 
 
29 
 
39.21 (1.15) 
 
0.7699 
TPO- 224 39.14 (1.10) 
Black 105 38.84 (1.12)  
 
TPO+ 
 
8 
 
38.75 (0.71) 
 
0.8181 
TPO- 97 38.84 (1.14) 
Hispanic 133 39.04 (1.08)  
 
TPO+ 
 
18 
 
38.78 (0.88) 
 
0.2753 
TPO- 115 39.08 (1.11) 
Other 37 38. 78 (1.06)  
 
TPO+ 
TPO- 
 
3 
34 
 
38.67 (1.15) 
38.79 (1.07) 
 
 
0.8447 
* Difference in gestational age by race/ethnicity is significant at p=0.0456 
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Table A.3 Mean head circumference at birth by maternal race/ethnicity and TPO status 
 
 
  
n 
Mean 
(±SD) 
 
P-value 
White 253 35.06 (1.36)  
 
TPO+ 
 
29 
 
34.28 (1.10) 
 
0.0009 
TPO- 224 35.16 (1.36) 
Black 105 34.36 (1.56)  
 
TPO+ 
 
8 
 
33.75 (1.91) 
 
0.2551 
TPO- 97 34.41 (1.55) 
Hispanic 133 34.72 (1.38)  
 
TPO+ 
 
18 
 
34.65 (1.25) 
 
0.1430 
TPO- 115 35.17 (1.40) 
Other 37 34.70 (1.43)  
 
TPO+ 
TPO- 
 
3 
34 
 
33.67 (0.58) 
34.79 (1.45) 
 
 
0.1949 
* Difference in head circumference by race/ethnicity is significant at p=0.0003 
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Table A.4Adjusted means of infant brain and body growth variables including preterm deliveries 
(N=569) 
 
 
 
Head Circumference 
 
TPO+ TPO- 
p- 
value 
CRUDE 34.26 (±0.23) 34.86   (±0.08) 0.1238 
ADJUSTED 34.36 (±0.15) 34.70   (±0.05) 0.0298 
Brain Weight 
CRUDE 327.47 (±5.42) 327.47 (±1.88) 0.1147 
ADJUSTED 329.57 (±3.72) 338.08 (±1.30) 0.0315 
 
Brain-to-Body Ratio  
CRUDE 9.97 (±0.16) 10.20 (±0.05) 0.1691 
ADJUSTED 9.89 (±0.11) 10.16 (±0.04) 0.0260 
 
Birth Weight  
CRUDE 3323.95 (±68.33) 3341.46 (±23.70) 0.8088 
ADJUSTED 3308.90 (±61.47) 3373.14 (±21.69) 0.3254 
 
Length 
CRUDE 50.76 (±0.34) 50.68 (±0.12) 0.8280 
ADJUSTED 50.83 (±0.20) 50.71 (±0.07) 0.5610 
 
Abdominal Circumference 
CRUDE 30.73 (±0.31) 31.09 (±0.11) 0.2900 
ADJUSTED 30.74 (±0.20) 31.09 (±0.07) 0.0999 
 
Chest Circumference  
CRUDE 33.00 (±0.29) 32.86 (±0.10) 0.6630 
ADJUSTED 33.05 (0.16) 32.87 (±0.05) 0.2921 
 
 
‡ Includes interaction term between maternal race and TPO status 
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B: SUPPLEMENTAL MATERIAL FOR MANUSCRIPT 2 
 
 
Table B.1 Selection of covariance structure for mixed models 
 
5 VISITS (BIRTH-6 MONTHS) [205 OBS] 
AUTOREGRESSIVE p AUTOREGRESSIVE p 
4 VISITS (3-6 MONTHS) [164 OBS] 
TPO -1.0781 0.1337 TPO1 -0.2672 0.4847 
TIME 2.0481 <.0001 TIME 0.9277 <.0001 
TPO*TIME 0.1563 0.4655 TPO1*TIME -0.00969 0.9279 
AIC 851.1  AIC 342.2  
BIC 854.5  BIC 345.7  
UNSTRUCTURED 
TPO1 
 
 
-0.4096 
 
 
0.3124 
UNSTRUCTURED 
TPO1 
 
 
-0.2245 
 
 
0.5279 
TIME 1.3932 <.0001 TIME 0.9548 <.0001 
TPO1*TIME 0.1034 0.1821 TPO1*TIME -0.02969 0.7303 
AIC 608.4  AIC 352.0  
BIC 634.1  BIC 369.1  
 
COMPOUND SYMMETRY COMPOUND SYMMETRY 
TPO -1.0367 0.1293 TPO1 -0.2138 0.531 
TIME 2.0144 <.0001 TIME 0.9424 <.0001 
TPO*TIME 0.1501 0.456 TPO1*TIME -0.03133 0.6658 
AIC 851.5  AIC 344.5  
BIC 854.9  BIC 348.0  
ANTE DEPENDENCE 
TPO 
 
 
-0.2069 
 
 
0.8238 
ANTE DEPENDENCE 
TPO1 
 
 
-0.3027 
 
 
0.6699 
TIME 0.8943 <.0001 TIME 0.933 <.0001 
TPO*TIME -0.01849 0.904 TPO1*TIME -0.0083 0.636 
AIC 616.0  AIC 351.5  
BIC 631.4  BIC 363.5  
TOEPLITZ 
TPO 
 
 
-1.5061 
 
 
0.0015 
TOEPLITZ 
TPO 
 
 
-0.2306 
 
 
0.5233 
TIME 2.2777 <.0001 TIME 0.9367 <.0001 
TPO*TIME 0.3381 0.0017 TPO*TIME -0.02381 0.7879 
AIC 804.3  AIC 341.6  
BIC 812.9  BIC 348.5  
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Table B.2 Model selection (5 visits) 
 
HEAD CIRCUMFERENCE AIC BIC 
Basic 614.3 636.6 
Basic + quadratic term 499.2 524.9 
Adjusted 571.1 602.0 
Adjusted + quadratic term 499.2 514.7 
 
WEIGHT 
Basic 545.7 561.1 
Basic + quadratic term 498.3 513.8 
Adjusted 537.6 553.0 
Adjusted + quadratic term 490.0 505.5 
 
LENGTH 
Basic 458.4 461.8 
Basic + quadratic term 410.9 414.3 
Adjusted 453.0 456.4 
Adjusted + quadratic term 405.3 408.8 
 
Basic: TPO+TIME+TPO*TIME 
Adjusted: Basic model + maternal race/ethnicity + maternal age + infant sex 
  
Table B.3 Model selection (4 visits)   
TPO 
 
 
 
HEAD WEIGHT LENGTH 
 Time AIC BIC AIC BIC AIC BIC 
 Random intercept + slope 317.8 324.7 341.8 348.7 267.8 276.3 
 Random intercept 316.0 321.2 348.3 353.4 275.6 280.7 
 Random slope 316.2 321.3 343.1 348.2 265.8 271.0 
 No random statement 314.4 317.9 346.4 349.8 279.3 282.8 
 
Time2  
 
Random intercept + slope+slope2 322.2 324.2 350.0 363.7 
 
 
Did not 
converge 
 Random intercept + slope  323.0 329.9 346.2 353.0 275.2 283.8 
Random intercept  321.4 326.5 352.6 357.8 283.2 288.3 
Random slope  321.2 326.4 347.3 352.4 273.3 278.5 
No random statement  319.6 322.0 350.7 354.1 287.0 290.4 
 PPT       
HEAD WEIGHT LENGTH 
 Time  AIC BIC AIC BIC AIC BIC 
 Random intercept + slope  176.2 180.6 167.2 171.6 168.0 173.4 
 Random intercept  177.3 180.6 166.4 168.6 168.6 171.9 
 Random slope  174.4 177.6 166.2 169.4 165.2 168.5 
 No random statement  177.3 179.5 166.4 168.6 168.1 170.2 
 
Time2 
 
 
Random intercept + slope+slope2 
 
 
185.2 
 
 
192.8 
 
 
172.9 
 
 
181.6 
 
 
175.1 
 
 
182.8 
 Random intercept + slope 181.8 186.1 167.7 172.1 173.3 283.8 
 Random intercept 182.8 186.1 167.1 169.3 174.0 177.3 
 Random slope 179.9 183.2 166.3 169.6 170.6 173.9 
 No random statement 182.7 184.9 167.1 169.3 173.4 175.6 
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APPENDIX C: STUDY DESIGN 
 
 
Dr. Maureen Groer, RN, PhD, FAAN is the principal investigator of the National Institutes of 
Health (NIH) R01 grant of which the dissertation study was funded as a research diversity 
supplement. 
Study Design of Parent Grant 
 
Pregnant women (N = 631) were recruited from prenatal clinics in Tampa, Florida and the 
surrounding area. Study participants were women first measured at mid-pregnancy (16-24 
weeks) and identified as either thyroid peroxidase antibody-positive (TPO+) or antibody– 
negative (TPO-). Inclusion criteria included pregnant women between the age 18 and 45 years 
of age who were able to understand and speak English or Spanish. Exclusion criteria included 
the following: known autoimmune disease, previous thyroid disease, HIV positivity, use of 
medications that affect immunity, chronic diseases, serious mental illness, body mass index 
(BMI) <20, history of hyperemesis, current multiple gestation, current pregnancy product of in 
vitro fertilization (IVF), fetal anomalies, and being unable to participate in a 6-month postpartum 
follow-up. 
All TPO-positive (n = 63) women were invited to participate in the postpartum phase of the 
study, whereas a convenience sample of TPO negative women were selected by a random 
number generator to participate in the postpartum phase (n = 72). Thyroid stimulating hormone 
(TSH) levels were measured for all TPO-positive women antenatally and at each postpartum 
visit.  TSH levels were measured on a subset of TPO-negative women postpartum (n=38). 
Women recruited into this study were visited each month in their home monthly by a research 
nurse for a 6 month follow-up periods. Participants received a graduated honorarium of $200 for 
completion of 6 months of data collection. 
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Women were not informed of their antibody status when they were invited to participate in the 
postpartum phase of the study. Over the course of the postpartum follow-up, women in the 
TPO+ group naturally formed 2 groups, those that developed postpartum thyroid dysfunction 
(PPTD) between 0 and 6 months postpartum and those who remained PPTD negative. The 
research nurse was blinded to prenatal TPO status. The mothers were also blinded to TPO 
status unless they were diagnosed with PPTD. All mothers in the study were visited in their 
homes starting at 7-10 days postpartum and monthly through 6 months postpartum, for a total of 
7 visits.  They received a graduated honorarium at each visit. The research nurse collected 
instruments, assessed potential of thyroid disease, weighed the participant, checked hematocrit, 
and performed a venipuncture. 
During the antenatal visit, participants completed a demographic questionnaire (Profile of Mood 
States [POMS])(101) and the Perceived Stress Scale (PSS)(102). At the subsequent 
postpartum visits, these stress and mood instruments were used in addition to an investigator- 
developed Thyroid Symptom Checklist. Data on breastfeeding, medications, health behaviors, 
and health status were also collected by an investigator-developed instrument. The long form of 
the POMS(101) is a 65-item rating scale for measuring how often a mood was experienced 
during the past week, including the day of measurement. The POMS consists of a total mood 
disturbance score and sixsubscales: tension-anxiety, depression-dejection, anger-hostility, 
vigor-activity, fatigue-inertia, and confusion-bewilderment. The internal consistency reliabilities 
for the subscales range from .87 to .95. The validity of the scale (face validity, factorial validity, 
predictive validity, and construct validity) is reported to be excellent(101). 
The PSS is used to measure levels of self-reported stress, and the 14-item version of the scale 
is used to evaluate subjects’ perception of stress with a Likert-type scale ranging from 0 (never) 
to 4 (very often). The internal consistency reliability was .84 to .86 in young adults. Congruent 
and criterion validity for the scale have been shown to be excellent, although predictive validity 
declines over time(102). 
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The Thyroid Symptom Checklist was based on the literature and clinical observations and 
designed to inventory the symptoms of hyper- and hypo-thyroidism. It consists of 19 symptoms 
on Likert-type scales between 0 (no symptom) to 4 (very severe). The woman is asked to rate 
symptoms including heat intolerance, dry hair and skin, puffy face, constipation, aches and 
pains, and so on. The validity of the scale was informally confirmed by an endocrinologist not 
associated with the study. 
Procedures 
 
TPO status was determined in 631 pregnant women’s plasma samples (collected between 16 
and 25 weeks of pregnancy) according to kit directions by ELISA (ORGENTEC, Mainz, 
Germany) using standards and controls. All samples were done in duplicate and titers recorded. 
The coefficient of variation was always less than 5%. TPO antibody titer greater than 20 IUs/ml 
was used as the cutoff value for determining positivity, as a value from 0 to 20 is considered the 
normal range(13). The research nurse who made the postpartum home visits to collect data was 
blinded to TPO status. At each postpartum home visit, participants received a targeted physical 
examination. 
Detailed data were gathered on the investigator developed demographic tool and included 
feeding type (exclusive or partial breastfeeding, or bottle feeding; ounces of formula per day), 
number of cigarettes smoked per day, alcohol consumption per day, and exercise (levels and 
minutes per day). A venipuncture was performed and 15 mls of blood were drawn into 
heparinized vacutainers. The blood was collected aseptically and transported to the laboratory 
within 2 hours. Immediately upon receipt, blood samples were centrifuged at 3,800 rpm for 25 
minutes at 4◦C. 
The plasma was aliquotted into multiple Eppendorf tubes and frozen at –80◦C until later analysis 
in batches. TSH (ALPCO, Salem, N.H.) was always measured at each visit for the TPO-positive 
women, regardless of symptoms, and assayed according to kit directions. TSH levels were also 
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measure for TPO-negative women with symptom reports on the Thyroid Screening Checklist 
indicating occurrence of hyper or hypo-thyroid symptoms. 
The decision to measure TSH in the lab was made by the investigator and not the research 
nurse to preserve blinding, as blood samples were taken from all participants for other  
measures in the parent study. Probable PPTD development was determined to occur when TSH 
levels of less than 0.3 or more than 3.0 mIU/L were measured(103). Women meeting these 
criteria for TSH were referred to their health care provider for further diagnostic workup and 
treatment. They were permitted to continue in the study, and all decided to complete the study. 
Accurate follow-up with health care providers was extremely difficult so we are unable to 
determine the natures of treatments these women received. 
 
 
Dissertation Study Design 
 
Participation in the parent grant did not infer participation in the longitudinal portion of the 
dissertation study. Therefore, a new consent form was created and submitted for IRB approval. 
Following approval, data collection for the proposed study was merged into the data collection 
methods of the parent grant. 
 
 
Data Collection 
Mothers who consented to participate in the longitudinal phase of the dissertation study were 
visited in their homes by appointment. The research nurse reviewed the mother’s demographic, 
stress and mood instruments and checked for missing data. In addition to measuring the 
mother’s weight, the research nurse drew blood and collected other information necessary for 
the parent grant objectives. Infant assessments were conducted as part of the data collection 
process for the dissertation research. Infant assessments began at 3 months of age and 
continued until the 6th month. 
Maternal Assessments 
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Infant neurocognitive function was assessed using the Bayley Scales of Infant Development, 
Third Edition (Bayley-III)18 Screening Test at 3 months of age. The norm referenced 
screening test assesses cognitive, motor and language skills and can be administered in 15 to 
25 minutes. The test indicates infant development through levels of risk categorized as 
“Competent”, “Emerging” and “At Risk”. At 6 months of age, infant’s neurocognitive 
characteristics were assessed using the full-scale Bayley-III which includes cognitive, language, 
and motor scales in addition to a social-emotional subtest (authored by Stanley Greenspan, 
Infant Assessments 
 
Antropometric measurements 
 
Newborn anthropometric measurements including birth weight (measured in pounds and 
grams), birth length (measured in inches and centimeters), and head circumference (cm) were 
retrieved from maternal delivery records. In the longitudinal phase of the study, infants were 
weighed with a digital portable scale (in pounds) (Unisar Model #BR149).  Body length was 
measured using a transportable Infantometer (in inches) (SECA 416 Mobile Infantometer). 
Additionally, head circumference was measured with a measuring tape (in centimeters). 
 
 
 
Neurocognitive assessment 
 
Prior to initiation of the dissertation, the principal investigator of the supplemental study, Ronee 
Wilson, audited a one-semester course titled “Psychological Assessments and Screening of 
Infants and Preschoolers (EDG 6931)” and receive mentorship under through the Children’s 
Medical Services (CMS) program at the University of South Florida to effectively administer the 
Bayley Scales of Infant Development, Third Edition (Bayley-III). Ms. Wilson shadowed Dr. 
Kathleen Armstrong, Director of USF Health Pediatric Psychology Program, and colleagues 
during infant assessments in the USF CMS clinic. 
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MD) and an adaptive behavior subtest (developed by Patti L. Harrison, PhD and Thomas 
Oakland, PhD). The norm referenced Bayley-III has been validated for children ages 1 to 42 
months. Administration of the Bayley-III can range from 30 to 90 minutes depending on the 
child’s age.  All infant assessments were conducted in the home environment. 
 
 
Covariates 
 
Based on previous research the following variables were examined for their confounding 
potential: maternal race/ethnicity, maternal age, education, marital status, and smoking habits. 
Other variables were considered covariates in analysis if bivariate associations exhibit a P value 
of 0.10 or less. The majority of the covariate was capture on the demographic form utilized by 
the parent grant which included maternal race, income, education, family history of thyroid 
disease, height and weight, exercise, problems during labor, birth history, mode of delivery, 
infant gender, postpartum complications, yearly income, family size, the presence of any chronic 
or acute health problems, smoking, current medications, birth history, work status, exercise, and 
breastfeeding or bottle-feeding history and current status. 
 
Strengths and Limitations 
 
This study offered a unique opportunity to assess the impact of maternal thyroid peroxidase 
status and postpartum thyroid dysfunction on infant growth and neurocognitive development. A 
notable strength of this study is the prospective design, as many of the previous studies were 
retrospective in nature. The outcome variables for manuscript 1 were extracted from maternal 
delivery records and for manuscript 2 the assessor was blinded to maternal thyroid peroxidase 
status, therefore, infant measurements were not influenced by knowledge of maternal TPO 
status. The use of mixed models maximized the potential of the data by allowing all available 
follow-up observations to be utilized in the analysis. 
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One limitation of this study was the lack of data on maternal iodine intake, as well as detailed 
information on smoking habits and/or alcohol  consumption during pregnancy including the 
amount of cigarettes and/or alcohol consumed and changes in these habits over the course of 
gestation. Low iodine intake, cigarette smoking and alcohol consumption may influence 
maternal thyroid function and thus perhaps fetal brain and body development. Additionally, the 
limited sample size reduced the power of some of the analysis and restricted the ability to 
adequately explore several areas of interest, including the influence of various potential 
confounders (e.g., breastfeeding habits, maternal obesity, maternal education, etc) on the 
relationship between TPO and/or PPTD status on infant outcomes. In addition, this study did not 
have enough power to sufficiently assess the influence of maternal TPO or PPTD status on 
infant neurocognitive outcomes. 
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APPENDIX D: SAMPLE SIZE AND POWER EVALUTION 
 
Sample size and power evaluation 
 
The PASS 2008 software was used to conduct sample size and power analysis for manuscripts 
1 and 2. For manuscript 1, using multiple regression analysis, a sample size of 528 participants 
was determined to have greater than 90% power to detect a 0.30 difference in infant 
anthropometric measurements attributed to 1 independent variable (TPO status) and adjusted 
for 9 additional independent variables with a significance level (alpha) of 0.05. For manuscript 2, 
it was determined that group sample sizes of 22 (TPO+) and 19 (TPO-) would achieve 90% 
power to detect a difference of 0.734 in a design with 5 repeated measurements having a AR(1) 
covariance structure when the standard deviation is 1.0, the correlation between observations 
on the same subject is 0.600, and the alpha level is 0.05. Analyses of differences in 
neurocognitive outcomes were underpowered due to the smaller than expected sample size. A 
priori sample size calculations were based on infant neuro-cognitive assessments using the 
Bayley-III scores. Type I and type II errors were set at 0.05 and 0.20, respectively. Based on 
the design of the parent grant it was anticipated that women would be enrolled at a 2:1 ratio of 
PPTD+ to PPTD- mothers. Table C1 depicts the sample size required in each group based on 
these parameters, an AR1 correlation structure and the desire to detect at least a 5 point 
difference on the Bayley-III. 
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Table D.1 Minimum sample size required to detect a 5 point difference on the Bayley-III using 
specified correlation coefficient parameters based on a 2:1 ratio of TPO+ to TPO- women, 
setting type I error to 0.05 and type II error to 0.20 
 
Ratio    AR1 Correlation    
▼    ρ=.3    ρ=.5  ρ=.7  
PPTD+ PPTD- PPTD+ PPTD- PPTD+ PPTD- 
2:1 82  41 110  55 144  72 
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Modification Request. The submitted request has been approved from 10/22/2009 to 7/22/2010 
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Dear Ms. Wilson: 
 
On 9/19/2010  the Institutional Review Board (IRB) reviewed and APPROVED the above 
referenced protocol. Please note that your approval for this study will expire on 9/19/2011.    
 
Approved Items: 
Protocol Document(s): 
Revised Study Protocol 9/17/2010 1:13 PM 0.02 
 
 
Consent/Assent Document(s): 
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It was the determination of the IRB that your study qualified for expedited review which 
includes activities that (1) present no more than minimal risk to human subjects, and (2) involve 
only procedures listed in one or more of the categories outlined below. The IRB may review 
research through the expedited review procedure authorized by 45CFR46.110 and 21 CFR 
56.110. The research proposed in this study is categorized under the following expedited review 
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(4) Collection of data through noninvasive procedures (not involving general anesthesia or 
sedation) routinely employed in clinical practice, excluding procedures involving x-rays or 
microwaves. Where medical devices are employed, they must be cleared/approved for 
marketing.  
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responsibility to conduct this study in accordance with IRB policies and procedures and as 
approved by the IRB. 
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Tampa, FL 33612 
 
RE:    Expedited Approval for Continuing Review 
          IRB#: Pro00001903 
          Title:   Developmental Assessment of Infants: A supplement to the “Screening for Thyroid 
Disease” study 
 
Study Approval Period: 9/19/2012 to 9/19/2013 
 
Dear Ms. Wilson: 
 
On 8/23/2012 the Institutional Review Board (IRB) reviewed and APPROVED the above 
protocol for the period indicated above.  It was the determination of the IRB that your study 
qualified for expedited review based on the federal expedited category number: 
 
(4) Collection of data through noninvasive procedures (not involving general anesthesia or 
sedation) routinely employed in clinical practice, excluding procedures involving x-rays or 
microwaves. Where medical devices are employed, they must be cleared/approved for 
marketing.  
  
Approved Item(s): 
Protocol Document(s): 
 
Revised Study Protocol 9/17/2010 1:13 PM 0.02 
   
 
Please reference the above IRB protocol number in all correspondence regarding this 
protocol with the IRB or the Division of Research Integrity and Compliance. It is your 
responsibility to conduct this study in accordance with IRB policies and procedures and as 
approved by the IRB. 
 
 
 
  
We appreciate your dedication to the ethical conduct of human subject research at the University 
of South Florida and your continued commitment to human research protections.  If you have 
any questions regarding this matter, please call 813-974-5638. 
 
Sincerely, 
 
Verena Jorgensen, M.D., Chairperson 
USF Institutional Review Board 
 
  
 
